Bevacizumab
Information
- Drug Name
- Bevacizumab
- Description
- Entry(CIViC)
- 16
CIViC
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Meta-Analysis of 12 studies with 2,266 patients (5... | KRAS | KRAS MUTATION KRAS MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| MMP2 serum levels were assessed (ELISA) at baselin... | MMP2 | MMP2 SERUM LEVELS MMP2 SERUM LEVELS | Sensitivity | true | CIViC Evidence | detail |
| MMP9 serum levels were assessed (ELISA) at baselin... | MMP9 | MMP9 SERUM LEVELS MMP9 SERUM LEVELS | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Plasma levels of 11 potential biomarkers were test... | MMP2 | MMP2 SERUM LEVELS MMP2 SERUM LEVELS | Sensitivity | true | CIViC Evidence | detail |
| Exome and RNA sequencing was performed in tumor an... | PPP1R15A |
PPP1R15A p.Arg251Pro (p.R251P) ( ENST00000200453.6, ENST00000600406.2, ENST00000704026.1, ENST00000704027.1 ) PPP1R15A p.Arg251Pro (p.R251P) ( ENST00000200453.6, ENST00000600406.2, ENST00000704026.1, ENST00000704027.1 ) |
Sensitivity | true | CIViC Evidence | detail |
| A patient with a malignant spindle cell tumor of t... | BRAF | BRAF KIAA1549-BRAF | Sensitivity | true | CIViC Evidence | detail |
| In a clinical study of 63 recurrent glioma patient... | IDH1 | IDH1 R132 IDH1 R132 | Sensitivity | true | CIViC Evidence | detail |
| In a study of metastatic colorectal cancer patient... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Resitance or Non-Reponse | true | CIViC Evidence | detail |
| In a clinical study of 63 recurrent glioma patient... | IDH1 | IDH1 R132 IDH1 R132 | Sensitivity | true | CIViC Evidence | detail |
| This was a retrospective clinical study of 97 meta... | KRAS | KRAS G12/G13 KRAS G12/G13 | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective clinical study of 97 meta... | PIK3CA | PIK3CA MUTATION PIK3CA MUTATION | Resitance or Non-Reponse | false | CIViC Evidence | detail |
| This was a retrospective clinical study of 97 meta... | BRAF | BRAF MUTATION BRAF MUTATION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Decreased peri- and post-therapeutic expression of... | VEGFA |
VEGFA UNDEREXPRESSION ( ENST00000372055.9 ) VEGFA UNDEREXPRESSION ( ENST00000372055.9 ) |
Sensitivity | true | CIViC Evidence | detail |
| Overexpression of EGFR exon 18 (Affymetrix Human E... | EGFR |
EGFR EXON 18 OVEREXPRESSION ( ENST00000344576.7 ) EGFR EXON 18 OVEREXPRESSION ( ENST00000344576.7 ) |
Sensitivity | true | CIViC Evidence | detail |
| EPHB4 expression, as assessed by quantitative RT-P... | EPHB4 | EPHB4 EXPRESSION EPHB4 EXPRESSION | Resitance or Non-Reponse | true | CIViC Evidence | detail |
| Mouse xenografts using HT29 cells harboring the BR... | BRAF |
BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) BRAF p.Val640Glu (p.V640E) ( ENST00000288602.11, ENST00000496384.7, ENST00000644969.2, ENST00000646891.2 ) |
Sensitivity | true | CIViC Evidence | detail |
| Uveal melanoma. Treatment with bevacizumab suppres... | VEGFA | VEGFA EXPRESSION | Sensitivity | true | MMMP | detail |
| Bevacizumab: anti-VEGF antibody. While in vitro no... | VEGFA | VEGFA EXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| Bevacizumab: anti-VEGF antibody. In vivo, in a sev... | EGFR | EGFR UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| This phase II RCT showed that addition of IFN to b... | IFNAR1 | IFNAR1 OVEREXPRESSION | Resitance or Non-Reponse | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03786081 | Active, not recruiting | Phase 1/Phase 2 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | February 27, 2019 | December 31, 2024 |
| NCT03363867 | Active, not recruiting | Phase 2 | BEACON - ABC in Recurrent Platinum Resistant HGSOC | July 10, 2018 | June 30, 2025 |
| NCT00324805 | Active, not recruiting | Phase 3 | Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery | June 1, 2007 | October 16, 2024 |
| NCT05330429 | Active, not recruiting | Phase 2 | Study of Magrolimab Given Together With FOLFIRI/BEV in Patients With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | July 8, 2022 | November 2026 |
| NCT03353831 | Active, not recruiting | Phase 3 | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | September 11, 2018 | December 1, 2024 |
| NCT03778957 | Active, not recruiting | Phase 3 | A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma | November 30, 2018 | August 31, 2026 |
| NCT02519348 | Active, not recruiting | Phase 2 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | October 19, 2015 | March 31, 2025 |
| NCT04660812 | Active, not recruiting | Phase 1/Phase 2 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | May 10, 2021 | July 2024 |
| NCT02436993 | Active, not recruiting | Phase 2 | Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab | April 2015 | June 2024 |
| NCT02364713 | Active, not recruiting | Phase 2 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | March 13, 2015 | February 28, 2028 |
| NCT02308527 | Active, not recruiting | Phase 2 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children | July 2013 | February 2026 |
| NCT03762018 | Active, not recruiting | Phase 3 | BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma | April 30, 2019 | June 2024 |
| NCT03351296 | Active, not recruiting | Phase 2 | Two Chemotherapy Regimens Plus or Minus Bevacizumab | June 26, 2018 | December 2028 |
| NCT02299999 | Active, not recruiting | Phase 2 | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | April 7, 2014 | December 2024 |
| NCT04164069 | Active, not recruiting | Phase 1 | Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab | September 2, 2020 | December 31, 2023 |
| NCT02210117 | Active, not recruiting | Early Phase 1 | Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery | November 25, 2014 | November 30, 2025 |
| NCT02142803 | Active, not recruiting | Phase 1 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | May 20, 2014 | October 1, 2024 |
| NCT03337698 | Active, not recruiting | Phase 1/Phase 2 | A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | January 2, 2018 | November 30, 2026 |
| NCT04487067 | Active, not recruiting | Phase 3 | A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | August 25, 2020 | August 13, 2024 |
| NCT03743662 | Active, not recruiting | Phase 2 | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | November 12, 2018 | November 2024 |
| NCT03329248 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | November 6, 2017 | December 2020 |
| NCT02138617 | Active, not recruiting | Phase 2 | Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer | May 2014 | June 1, 2027 |
| NCT04158258 | Active, not recruiting | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America | February 21, 2020 | November 28, 2025 | |
| NCT02020707 | Active, not recruiting | Phase 1 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | February 24, 2014 | June 30, 2025 |
| NCT03326193 | Active, not recruiting | Phase 2 | A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | December 12, 2017 | May 31, 2024 |
| NCT03307785 | Active, not recruiting | Phase 1 | Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | October 12, 2017 | August 30, 2024 |
| NCT03280563 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | December 26, 2017 | December 31, 2024 |
| NCT02017717 | Active, not recruiting | Phase 3 | A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients | February 7, 2014 | April 8, 2024 |
| NCT03193190 | Active, not recruiting | Phase 1/Phase 2 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) | July 5, 2017 | October 31, 2026 |
| NCT04406272 | Active, not recruiting | Phase 2 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | August 1, 2020 | August 1, 2024 |
| NCT01950390 | Active, not recruiting | Phase 2 | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | January 24, 2014 | January 7, 2025 |
| NCT04121455 | Active, not recruiting | Phase 1/Phase 2 | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | September 12, 2019 | December 2024 |
| NCT04109924 | Active, not recruiting | Phase 2 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | December 27, 2019 | July 17, 2024 |
| NCT04102098 | Active, not recruiting | Phase 3 | A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | December 31, 2019 | July 16, 2027 |
| NCT03186326 | Active, not recruiting | Phase 2 | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | April 24, 2018 | May 31, 2023 |
| NCT03740165 | Active, not recruiting | Phase 3 | Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036) | December 18, 2018 | May 29, 2026 |
| NCT05824559 | Active, not recruiting | Phase 1 | ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer | August 7, 2023 | June 30, 2024 |
| NCT03737643 | Active, not recruiting | Phase 3 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients | January 4, 2019 | May 25, 2028 |
| NCT04245085 | Active, not recruiting | Phase 2 | ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma | September 29, 2020 | December 2024 |
| NCT00334815 | Active, not recruiting | Phase 2 | Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | June 15, 2006 | February 22, 2025 |
| NCT03181100 | Active, not recruiting | Phase 2 | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | July 27, 2017 | July 31, 2025 |
| NCT01946529 | Active, not recruiting | Phase 2 | Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors | December 27, 2013 | July 2026 |
| NCT03175432 | Active, not recruiting | Phase 2 | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | June 15, 2017 | June 30, 2026 |
| NCT04854668 | Active, not recruiting | Phase 3 | A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer | July 30, 2020 | December 31, 2025 |
| NCT03148418 | Active, not recruiting | Phase 3 | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | September 20, 2017 | March 6, 2030 |
| NCT01932125 | Active, not recruiting | Phase 4 | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | December 5, 2018 | June 21, 2025 |
| NCT01871766 | Active, not recruiting | Phase 2 | Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy | December 4, 2013 | June 2030 |
| NCT04094688 | Active, not recruiting | Phase 3 | Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer | September 30, 2019 | July 2025 |
| NCT00433511 | Active, not recruiting | Phase 3 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | November 2, 2007 | February 22, 2025 |
| NCT03661723 | Active, not recruiting | Phase 2 | Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma | September 28, 2018 | June 1, 2024 |
| NCT03635567 | Active, not recruiting | Phase 3 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | October 25, 2018 | June 4, 2024 |
| NCT03141684 | Active, not recruiting | Phase 2 | Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma | April 25, 2017 | October 31, 2025 |
| NCT01871571 | Active, not recruiting | Phase 2 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | August 2, 2013 | June 24, 2023 |
| NCT03133546 | Active, not recruiting | Phase 2 | Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER) | May 31, 2017 | May 2023 |
| NCT05839951 | Active, not recruiting | An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions | April 24, 2023 | October 31, 2024 | |
| NCT01802749 | Active, not recruiting | Phase 3 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | November 2013 | December 2023 |
| NCT03635021 | Active, not recruiting | Phase 3 | Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer | October 15, 2018 | June 28, 2025 |
| NCT04837716 | Active, not recruiting | Phase 1 | Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer | March 18, 2021 | September 23, 2027 |
| NCT04829383 | Active, not recruiting | Phase 2 | A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | March 22, 2021 | October 2025 |
| NCT05112861 | Active, not recruiting | Phase 3 | A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders | November 15, 2021 | March 2025 |
| NCT03596281 | Active, not recruiting | Phase 1 | Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer | December 5, 2018 | April 2023 |
| NCT03587311 | Active, not recruiting | Phase 2 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | October 12, 2018 | October 21, 2024 |
| NCT03586869 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.080: NANT Pancreatic Cancer Vaccine | July 28, 2018 | December 2019 |
| NCT03556839 | Active, not recruiting | Phase 3 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix | September 25, 2018 | November 2024 |
| NCT01746238 | Active, not recruiting | Phase 1 | Bevacizumab/Doxorubicin/Radiation for Sarcoma | March 2013 | January 2025 |
| NCT03117972 | Active, not recruiting | Phase 2 | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels | August 4, 2017 | December 2025 |
| NCT05191784 | Active, not recruiting | Phase 2 | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | January 26, 2022 | December 31, 2024 |
| NCT01743950 | Active, not recruiting | Phase 2 | A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab | December 3, 2012 | December 2025 |
| NCT04761614 | Active, not recruiting | Phase 1 | Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | April 2, 2021 | December 31, 2024 |
| NCT03074513 | Active, not recruiting | Phase 2 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | March 3, 2017 | September 30, 2025 |
| NCT01706120 | Active, not recruiting | Phase 4 | Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab | October 2012 | December 2024 |
| NCT01684397 | Active, not recruiting | Phase 1/Phase 2 | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer | November 21, 2012 | January 2, 2025 |
| NCT02974621 | Active, not recruiting | Phase 2 | Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma | December 7, 2017 | July 20, 2024 |
| NCT05211323 | Active, not recruiting | Phase 2 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | December 7, 2022 | January 31, 2025 |
| NCT02971501 | Active, not recruiting | Phase 2 | Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases | June 27, 2018 | July 1, 2024 |
| NCT00565851 | Active, not recruiting | Phase 3 | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | December 6, 2007 | January 1, 2028 |
| NCT04227028 | Active, not recruiting | Phase 1 | Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC | March 9, 2020 | November 1, 2024 |
| NCT01552434 | Active, not recruiting | Phase 1 | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease | March 16, 2012 | March 31, 2026 |
| NCT00569127 | Active, not recruiting | Phase 3 | Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor | December 1, 2007 | January 31, 2025 |
| NCT02934529 | Active, not recruiting | Phase 3 | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab | March 2015 | December 2024 |
| NCT02873962 | Active, not recruiting | Phase 2 | A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib | November 10, 2016 | July 2026 |
| NCT04074785 | Active, not recruiting | Early Phase 1 | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 | December 13, 2019 | October 24, 2025 |
| NCT04194203 | Active, not recruiting | Phase 3 | A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | April 9, 2020 | June 28, 2024 |
| NCT03532295 | Active, not recruiting | Phase 2 | Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas | April 20, 2020 | April 25, 2026 |
| NCT02873195 | Active, not recruiting | Phase 2 | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | July 7, 2017 | July 1, 2024 |
| NCT01217931 | Active, not recruiting | Phase 2 | Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | January 19, 2011 | January 31, 2025 |
| NCT03526432 | Active, not recruiting | Phase 2 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | August 8, 2018 | May 2025 |
| NCT05359861 | Active, not recruiting | Phase 2 | Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | April 12, 2022 | May 2026 |
| NCT01191697 | Active, not recruiting | Phase 2 | CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | February 2011 | July 2024 |
| NCT00588770 | Active, not recruiting | Phase 3 | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | August 8, 2008 | February 22, 2025 |
| NCT04034459 | Active, not recruiting | Phase 2 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | November 25, 2016 | December 31, 2023 |
| NCT05200364 | Active, not recruiting | Phase 1 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | March 22, 2022 | January 2026 |
| NCT04952753 | Active, not recruiting | Phase 2 | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC | November 15, 2021 | September 12, 2024 |
| NCT01187199 | Active, not recruiting | Phase 1 | Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer | August 19, 2010 | April 30, 2026 |
| NCT05141721 | Active, not recruiting | Phase 2/Phase 3 | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | February 12, 2022 | March 2027 |
| NCT02840409 | Active, not recruiting | Phase 2 | Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG) | August 1, 2016 | August 2026 |
| NCT04743661 | Active, not recruiting | Phase 2 | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | April 4, 2022 | October 30, 2030 |
| NCT00601900 | Active, not recruiting | Phase 3 | Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer | May 15, 2008 | July 10, 2024 |
| NCT00861705 | Active, not recruiting | Phase 2 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | May 15, 2009 | February 22, 2025 |
| NCT02839707 | Active, not recruiting | Phase 2/Phase 3 | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | June 23, 2017 | September 21, 2024 |
| NCT01167712 | Active, not recruiting | Phase 3 | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | September 27, 2010 | June 7, 2024 |
| NCT02794571 | Active, not recruiting | Phase 1 | Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors | May 23, 2016 | October 5, 2024 |
| NCT03498521 | Active, not recruiting | Phase 2 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site | July 10, 2018 | June 9, 2024 |
| NCT04175470 | Active, not recruiting | Phase 2 | Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer | October 29, 2019 | December 2024 |
| NCT01130519 | Active, not recruiting | Phase 2 | A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer | May 6, 2010 | December 1, 2024 |
| NCT00873275 | Active, not recruiting | Phase 1 | Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | March 11, 2009 | January 13, 2025 |
| NCT02761070 | Active, not recruiting | Phase 3 | Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III | July 11, 2016 | November 10, 2025 |
| NCT04940546 | Active, not recruiting | Phase 1/Phase 2 | Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients | June 16, 2021 | October 30, 2024 |
| NCT05733611 | Active, not recruiting | Phase 2 | RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | June 29, 2023 | March 1, 2027 |
| NCT04730999 | Active, not recruiting | Phase 2 | Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer | July 1, 2020 | October 17, 2024 |
| NCT03991403 | Active, not recruiting | Phase 3 | Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | August 27, 2019 | March 11, 2024 |
| NCT05611645 | Active, not recruiting | Phase 2 | Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence | October 1, 2022 | December 2025 |
| NCT04683965 | Active, not recruiting | Phase 2 | Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer | January 1, 2021 | May 1, 2024 |
| NCT02734004 | Active, not recruiting | Phase 1/Phase 2 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | March 17, 2016 | September 17, 2025 |
| NCT03961698 | Active, not recruiting | Phase 2 | Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma | December 17, 2019 | August 31, 2023 |
| NCT05678257 | Active, not recruiting | Phase 2 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | April 18, 2023 | March 2025 |
| NCT05116189 | Active, not recruiting | Phase 3 | Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) | December 13, 2021 | August 31, 2027 |
| NCT02724878 | Active, not recruiting | Phase 2 | Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma | July 2016 | October 2024 |
| NCT03475004 | Active, not recruiting | Phase 2 | Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | September 17, 2018 | December 31, 2024 |
| NCT02698254 | Active, not recruiting | N/A | Radiation Therapy in Treating Patients With Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy | July 20, 2016 | July 1, 2025 |
| NCT03451370 | Active, not recruiting | First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer | November 1, 2017 | December 2024 | |
| NCT03929666 | Active, not recruiting | Phase 2 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | August 29, 2019 | October 30, 2026 |
| NCT02671435 | Active, not recruiting | Phase 1/Phase 2 | A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors | February 22, 2016 | September 2, 2024 |
| NCT03390686 | Active, not recruiting | Phase 3 | A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | November 15, 2019 | July 2024 |
| NCT01081262 | Active, not recruiting | Phase 3 | Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer | October 12, 2010 | March 1, 2025 |
| NCT02669173 | Active, not recruiting | Phase 1 | Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma | October 11, 2016 | November 1, 2024 |
| NCT03890952 | Active, not recruiting | Phase 2 | Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma | October 1, 2018 | August 1, 2023 |
| NCT02633189 | Active, not recruiting | Phase 3 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer | April 2016 | July 2024 |
| NCT01061515 | Active, not recruiting | Phase 1 | Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer | May 10, 2011 | September 27, 2024 |
| NCT03847428 | Active, not recruiting | Phase 3 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment | April 29, 2019 | May 31, 2027 |
| NCT05593328 | Active, not recruiting | Phase 2 | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | March 17, 2023 | April 2026 |
| NCT00217737 | Active, not recruiting | Phase 3 | Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer | September 6, 2005 | September 30, 2024 |
| NCT03818061 | Active, not recruiting | Phase 2 | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck | March 26, 2019 | March 1, 2024 |
| NCT00977574 | Active, not recruiting | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | September 14, 2009 | March 6, 2025 |
| NCT03798626 | Active, not recruiting | Phase 1 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | May 22, 2019 | December 30, 2024 |
| NCT03387111 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed | January 13, 2018 | April 2021 |
| NCT03387085 | Active, not recruiting | Phase 1/Phase 2 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | March 16, 2018 | October 2023 |
| NCT04931342 | Active, not recruiting | Phase 2 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | October 7, 2021 | December 31, 2028 |
| NCT00321646 | Completed | Phase 2 | Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy | June 2006 | December 2012 |
| NCT00321685 | Completed | Phase 2 | Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer | July 25, 2006 | February 11, 2019 |
| NCT00321828 | Completed | Phase 2 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery | March 2006 | December 2012 |
| NCT00323739 | Completed | Phase 2 | Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma | May 2006 | March 2011 |
| NCT00323869 | Completed | Phase 2 | Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer | June 2006 | October 2013 |
| NCT00324870 | Completed | Phase 1/Phase 2 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | February 2006 | November 2013 |
| NCT00333775 | Completed | Phase 3 | A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer | March 2006 | October 2013 |
| NCT00335829 | Completed | Phase 2 | Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | May 2006 | February 2011 |
| NCT00336323 | Completed | Phase 2 | A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin) | June 2006 | February 2008 |
| NCT00337207 | Completed | Phase 2 | Bevacizumab in Treating Patients With Recurrent or Progressive Glioma | March 2006 | May 2009 |
| NCT00343044 | Completed | Phase 2 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | June 2006 | August 2011 |
| NCT00343291 | Completed | Phase 2 | A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC | December 2006 | December 2010 |
| NCT00345163 | Completed | Phase 2 | A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN) | July 2006 | September 2007 |
| NCT00345696 | Completed | Phase 2 | 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. | June 2006 | January 2011 |
| NCT00345761 | Completed | Phase 1/Phase 2 | Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer | February 2006 | July 2010 |
| NCT00352521 | Completed | Phase 2 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma | April 2006 | July 2009 |
| NCT00354679 | Completed | Phase 2 | Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer | April 2006 | June 2015 |
| NCT00354978 | Completed | Phase 2 | Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients | January 2005 | March 2011 |
| NCT00356031 | Completed | Phase 2 | Bevacizumab and Radiation Therapy for Sarcomas | July 2006 | March 2010 |
| NCT00356122 | Completed | Phase 2 | Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) | July 2006 | August 2010 |
| NCT00356889 | Completed | Phase 2 | Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors | May 2006 | June 2010 |
| NCT00357318 | Completed | Phase 1 | Bevacizumab and Sunitinib in Treating Patients With Solid Tumors | June 2006 | |
| NCT00360360 | Completed | Phase 2 | Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site | July 2006 | March 2009 |
| NCT00361231 | Completed | Phase 2 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer | May 2006 | August 2012 |
| NCT00364611 | Completed | Phase 2 | Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer | August 2006 | April 2012 |
| NCT00365144 | Completed | Phase 2 | Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine | February 2006 | March 2010 |
| NCT00365391 | Completed | Phase 2 | Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer | August 2006 | June 2010 |
| NCT00365417 | Completed | Phase 2 | Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | August 2006 | November 2009 |
| NCT00365547 | Completed | Phase 2 | Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy | September 2006 | September 2011 |
| NCT00366457 | Completed | Phase 2 | Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer | August 2006 | July 2011 |
| NCT00367601 | Completed | Phase 2 | Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer | August 2006 | December 2008 |
| NCT00368875 | Completed | Phase 1/Phase 2 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | July 2006 | December 2011 |
| NCT00368992 | Completed | Phase 2 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | August 2006 | October 2010 |
| NCT00369122 | Completed | Phase 2 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | August 11, 2006 | December 15, 2016 |
| NCT00369889 | Completed | Phase 2 | A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer | August 2006 | September 2007 |
| NCT00370786 | Completed | Phase 3 | Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV) | November 2005 | February 2008 |
| NCT00373256 | Completed | Phase 3 | A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer | November 2006 | August 2011 |
| NCT00376701 | Completed | Phase 2 | Combination Therapy for Age-Related Macular Degeneration. | September 2006 | April 2009 |
| NCT00378066 | Completed | Phase 2 | Phase II Study of Bevacizumab, Capecitabine and Oxaliplatin in Colon Cancer | August 2006 | October 2008 |
| NCT00378703 | Completed | Phase 2 | Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer | September 14, 2007 | March 21, 2017 |
| NCT00381797 | Completed | Phase 2 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | August 2006 | October 2015 |
| NCT00384176 | Completed | Phase 2/Phase 3 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX | August 30, 2006 | August 19, 2015 |
| NCT00387374 | Completed | Phase 2 | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | October 2006 | |
| NCT00387699 | Completed | Phase 2 | Bevacizumab, Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer | October 2006 | April 2014 |
| NCT00387751 | Completed | Phase 2 | Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma | August 2006 | January 2010 |
| NCT00390156 | Completed | Phase 1 | Imatinib, Bevacizumab, and Cyclophosphamide in Patients With Refractory Metastatic Solid Tumors | August 2006 | January 2011 |
| NCT00392392 | Completed | Phase 2 | Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer | October 2006 | December 2011 |
| NCT00392704 | Completed | Phase 2 | Treatment of Head & Neck Cancer With Chemotherapy and Radiation | December 2006 | May 2012 |
| NCT00393068 | Completed | Phase 2 | Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer | February 2007 | August 2011 |
| NCT00393497 | Completed | Phase 1 | A Pilot Study of VEGF Inhibition in Patients With Lymphedema Following Breast Cancer Treatment | April 2007 | January 2011 |
| NCT00394082 | Completed | Phase 2 | ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer | June 1, 2006 | February 1, 2011 |
| NCT00394251 | Completed | Phase 2 | Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | August 1, 2006 | February 1, 2008 |
| NCT00394433 | Completed | Phase 2 | Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | September 2006 | October 2016 |
| NCT00397982 | Completed | Phase 2 | Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma | January 2008 | July 2013 |
| NCT00398320 | Completed | Phase 2 | Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors | November 2006 | October 2012 |
| NCT00399750 | Completed | Phase 2 | TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer | November 2002 | June 2005 |
| NCT00401817 | Completed | Phase 2 | Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma | November 2007 | November 2013 |
| NCT00403130 | Completed | Phase 2 | Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer | February 2006 | November 2012 |
| NCT00403403 | Completed | Phase 2 | A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE) | March 2007 | June 2009 |
| NCT00405405 | Completed | Phase 1 | Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer | December 2006 | June 2010 |
| NCT00405938 | Completed | Phase 2 | Bevacizumab Given With Either Anastrozole or Fulvestrant With Trastuzumab for Postmenopausal Metastatic Breast Cancer | November 2006 | June 2011 |
| NCT00407563 | Completed | Phase 2 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | January 2007 | February 2011 |
| NCT00407719 | Completed | Phase 1 | Bevicizumab (Avastin) Infusion for Choroidal Neovascularization (CNV) Not Associated With Age-Related Macular Degeneration (AMD) | June 2005 | May 2008 |
| NCT00408694 | Completed | Phase 2 | Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer | December 13, 2006 | December 15, 2011 |
| NCT00409565 | Completed | Phase 2 | A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer | September 2006 | February 2012 |
| NCT00410605 | Completed | Phase 2 | Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | November 2006 | June 2014 |
| NCT00410956 | Completed | Phase 2 | Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery | May 9, 2007 | May 7, 2024 |
| NCT00416494 | Completed | Phase 2 | Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer | September 2003 | August 2014 |
| NCT00417976 | Completed | Phase 2 | Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer | December 2006 | February 2011 |
| NCT00418938 | Completed | Phase 2 | SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | November 1, 2006 | April 1, 2013 |
| NCT00423059 | Completed | N/A | Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy | December 2006 | March 2007 |
| NCT00423696 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | March 23, 2006 | August 1, 2011 |
| NCT00423917 | Completed | Phase 2 | Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer | August 2007 | January 15, 2017 |
| NCT00423930 | Completed | Phase 2 | Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | October 2006 | July 2016 |
| NCT00425646 | Completed | Phase 2 | Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | November 2006 | July 2009 |
| NCT00426998 | Completed | Phase 2 | Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD | April 2006 | |
| NCT00428545 | Completed | Phase 1 | Bevacizumab and Bortezomib in Patients With Advanced Malignancy | January 2007 | November 2012 |
| NCT00428922 | Completed | Phase 2 | Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients | June 14, 2007 | February 7, 2017 |
| NCT00433381 | Completed | Phase 2 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | March 1, 2007 | February 16, 2011 |
| NCT00434252 | Completed | Phase 2 | A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma | February 2007 | April 2009 |
| NCT00434642 | Completed | Phase 3 | A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma | April 2007 | July 2013 |
| NCT00436215 | Completed | Phase 2 | Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer | December 12, 2006 | September 27, 2014 |
| NCT00436332 | Completed | Phase 2 | S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma | July 2007 | August 20, 2019 |
| NCT00444041 | Completed | Phase 1/Phase 2 | Pre- and Postoperative Chemotherapy Including Bevacizumab in Potentially Curable Metastatic Colorectal Cancer | January 2007 | December 2009 |
| NCT00444535 | Completed | Phase 2 | Lapatinib and Bevacizumab for Metastatic Breast Cancer | February 27, 2007 | June 19, 2020 |
| NCT00445406 | Completed | Phase 2 | Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer | December 2006 | March 2009 |
| NCT00445848 | Completed | Phase 2 | S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer | July 2007 | January 2014 |
| NCT00446030 | Completed | Phase 2 | Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer | March 2007 | August 2010 |
| NCT00448019 | Completed | Phase 2 | FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) | February 2007 | October 2014 |
| NCT00450827 | Completed | Phase 1 | Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma | August 2006 | August 2015 |
| NCT00455975 | Completed | Phase 2 | High-dose Bevacizumab in Advanced Renal Carcinoma Patients | February 2007 | September 2013 |
| NCT00456261 | Completed | Phase 2 | First-Line Treatment of A Comparison of 2 Treatments in Elderly Patients With Advanced NSCLC | March 2007 | September 2012 |
| NCT00458731 | Completed | Phase 1 | Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma | May 2007 | |
| NCT00460174 | Completed | Phase 2 | Gemcitabine, Bevacizumab, and Abdominal Radiation Therapy in Treating Patients With Localized Pancreatic Cancer | October 10, 2005 | July 16, 2010 |
| NCT00460603 | Completed | Phase 1/Phase 2 | Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer | January 2006 | November 2012 |
| NCT00462501 | Completed | N/A | Combination Chemotherapy and Bevacizumab With or Without Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer | March 2007 | February 2014 |
| NCT00463073 | Completed | Phase 2 | Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas | August 2006 | December 2008 |
| NCT00463203 | Completed | Phase 2 | Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy | March 2007 | June 2011 |
| NCT00464646 | Completed | Phase 2 | Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | May 2007 | May 2014 |
| NCT00466687 | Completed | Phase 2 | Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma | September 2004 | September 2008 |
| NCT00467012 | Completed | Phase 2 | Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer | April 2007 | September 2011 |
| NCT00467142 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | January 23, 2007 | December 2011 |
| NCT00467194 | Completed | Phase 1 | Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | December 2006 | |
| NCT00468585 | Completed | Phase 1/Phase 2 | Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model | June 2005 | April 2011 |
| NCT00469443 | Completed | Phase 3 | Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC | December 2006 | February 2010 |
| NCT00473590 | Completed | Phase 2 | A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER) | June 2007 | November 2009 |
| NCT00479674 | Completed | Phase 2 | Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer | May 2007 | March 2014 |
| NCT00480831 | Completed | Phase 2 | A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | June 2007 | August 2010 |
| NCT00482495 | Completed | Phase 2 | Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | April 2006 | November 2009 |
| NCT00483782 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | April 2006 | |
| NCT00483834 | Completed | Phase 2 | A Phase II Study of Bevacizumab, Irinotecan and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer | December 2006 | July 2011 |
| NCT00484939 | Completed | Phase 3 | A Study of Bevacizumab (Avastin) in Combination With Capecitabine (Xeloda) in Elderly Patients With Metastatic Colorectal Cancer | July 2007 | March 2013 |
| NCT00491855 | Completed | Phase 1 | Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | June 2007 | December 2012 |
| NCT00492089 | Completed | Phase 2 | Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer | June 2007 | August 2010 |
| NCT00496587 | Completed | Phase 2 | Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma | July 2007 | May 2016 |
| NCT00497497 | Completed | Phase 1 | A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g) | October 2007 | September 2010 |
| NCT00499694 | Completed | N/A | Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With Docetaxel | October 2007 | November 2012 |
| NCT00501891 | Completed | Phase 2 | Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma | July 2007 | November 2009 |
| NCT00508625 | Completed | Phase 2 | A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | June 2006 | November 2011 |
| NCT00511459 | Completed | Phase 2 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | July 2007 | May 2014 |
| NCT00513786 | Completed | Phase 2 | Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | August 1, 2007 | January 3, 2017 |
| NCT00516295 | Completed | Phase 2 | Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma | February 2008 | January 2010 |
| NCT00520013 | Completed | Phase 2 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | August 2007 | November 2013 |
| NCT00525525 | Completed | Phase 2 | Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | September 2007 | May 2013 |
| NCT00528567 | Completed | Phase 3 | BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer | December 2007 | June 2014 |
| NCT00530907 | Completed | Phase 1 | Valproic Acid and Bevacizumab in Patients With Advanced Cancer | June 2007 | November 2013 |
| NCT00531024 | Completed | Phase 2/Phase 3 | Systemic Avastin Therapy in Age-Related Macular Degeneration | August 2005 | March 2008 |
| NCT00531960 | Completed | Phase 2 | A Study of Tarceva (Erlotinib) in Combination With Avastin (Bevacizumab) in Patients With Advanced Non-Small Cell Lung Cancer. | January 2008 | January 2010 |
| NCT00532909 | Completed | Phase 1 | Phase I Vandetanib Plus Capecitabine, Oxaliplatin and Bevacizumab for Metastatic Colorectal Cancer | July 2006 | May 2010 |
| NCT00533429 | Completed | Phase 2 | Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy | October 2007 | February 2009 |
| NCT00533585 | Completed | Phase 1 | BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) | May 2006 | January 2016 |
| NCT00536640 | Completed | Phase 2 | Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab | November 2007 | May 2012 |
| NCT00537901 | Completed | N/A | First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study | October 2007 | October 2013 |
| NCT00541099 | Completed | Phase 2 | Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | January 2008 | January 2013 |
| NCT00541125 | Completed | Phase 2 | G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer | November 2007 | December 2013 |
| NCT00543504 | Completed | Phase 1 | Bevacizumab in Multiple Phase I Combinations | October 10, 2007 | April 29, 2020 |
| NCT00543842 | Completed | Phase 1 | Bevacizumab, Erlotinib, and Capecitabine for Locally Advanced Rectal Cancer | December 2007 | December 2013 |
| NCT00545077 | Completed | Phase 3 | Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women | November 6, 2007 | July 24, 2014 |
| NCT00545870 | Completed | Phase 3 | Bevacizumab Versus Ranibizumab for Diabetic Retinopathy | June 2008 | April 2013 |
| NCT00546156 | Completed | Phase 2 | Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer | October 2007 | December 2012 |
| NCT00548197 | Completed | Phase 1 | Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment | February 2007 | March 2008 |
| NCT00548418 | Completed | Phase 2 | Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer | February 2007 | December 2012 |
| NCT00548548 | Completed | Phase 3 | A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer | September 2007 | November 2013 |
| NCT00550537 | Completed | Phase 2 | Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | October 2007 | December 2013 |
| NCT00550927 | Completed | Phase 1 | Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer | November 2006 | September 2012 |
| NCT00553800 | Completed | Phase 2 | Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer | July 5, 2007 | June 1, 2011 |
| NCT00556348 | Completed | Phase 4 | Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration | November 2005 | November 2008 |
| NCT00557232 | Completed | Phase 4 | Intraocular Bevacizumab (Avastin) for Rubeosis Iridis | November 2006 | November 2011 |
| NCT00559845 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Patients With Inflammatory or Locally Advanced Breast Cancer | February 2008 | July 2015 |
| NCT00568048 | Completed | Phase 2 | Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | December 2007 | October 2011 |
| NCT00576199 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) and Transarterial Chemoembolisation (TACE) Treatment in Patients With Liver Cancer | February 2008 | May 2011 |
| NCT00578149 | Completed | Phase 2 | Bevacizumab and Carboplatin/Paclitaxel and Radiation in Non-Small Cell Lung Cancer | May 2006 | August 2007 |
| NCT00580333 | Completed | Phase 2 | Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer | September 2007 | June 2020 |
| NCT00586508 | Completed | Phase 2 | Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas | November 2007 | October 2013 |
| NCT00588666 | Completed | Phase 2 | Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma | May 2006 | December 2011 |
| NCT00591734 | Completed | Phase 2 | RAD001 Plus Bevacizumab in Metastatic Melanoma | January 2008 | October 2011 |
| NCT00593450 | Completed | Phase 3 | Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial | February 2008 | April 2015 |
| NCT00596297 | Completed | Phase 1/Phase 2 | Preoperative Bevacizumab for Vitreous Hemorrhage | November 2007 | September 2008 |
| NCT00597506 | Completed | Phase 2 | Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus | October 2007 | June 2010 |
| NCT00600821 | Completed | Phase 2 | A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. | April 2008 | October 2012 |
| NCT00602602 | Completed | Phase 2 | Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer | March 2007 | September 2011 |
| NCT00608972 | Completed | Phase 2 | Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer | May 16, 2008 | September 25, 2015 |
| NCT00610493 | Completed | Phase 1 | Bevacizumab and Temsirolimus in Patients With Advanced Malignancy | January 25, 2008 | November 28, 2017 |
| NCT00614653 | Completed | Phase 1 | Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer | January 2008 | July 2016 |
| NCT00618657 | Completed | Phase 2 | Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | February 2008 | July 2021 |
| NCT00619268 | Completed | Phase 2 | Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma | February 2008 | February 2012 |
| NCT00620971 | Completed | Phase 2 | Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC | January 2008 | April 2010 |
| NCT00621686 | Completed | Phase 2 | Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme | September 2008 | February 19, 2014 |
| NCT00623233 | Completed | Phase 2 | Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer | March 2008 | January 2011 |
| NCT00623805 | Completed | Phase 3 | A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer | March 2008 | May 2012 |
| NCT00625651 | Completed | Phase 1/Phase 2 | Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer | October 2007 | September 2011 |
| NCT00626405 | Completed | Phase 2 | Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery | August 2008 | November 2012 |
| NCT00628810 | Completed | Phase 2 | Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | January 2007 | December 2008 |
| NCT00631371 | Completed | Phase 3 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects | April 2008 | April 2015 |
| NCT00636610 | Completed | Phase 2 | A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer | May 2008 | December 2010 |
| NCT00642759 | Completed | Phase 2 | Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer | April 2008 | April 2015 |
| NCT00653939 | Completed | Phase 2 | A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer | March 2008 | October 2011 |
| NCT00654836 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | October 2007 | September 2015 |
| NCT00656435 | Completed | Phase 3 | Bevacizumab and Long Acting Gas in Diabetic Vitrectomy | December 2006 | February 2008 |
| NCT00658697 | Completed | Phase 2 | Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer | June 2008 | June 2015 |
| NCT00661154 | Completed | Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project | February 2008 | July 2010 | |
| NCT00661778 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer | July 2007 | July 2011 |
| NCT00662129 | Completed | Phase 2 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Gemcitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | November 2008 | August 2013 |
| NCT00665990 | Completed | Phase 1 | Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia | November 2007 | August 2013 |
| NCT00667342 | Completed | Phase 2 | A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | June 3, 2008 | August 2017 |
| NCT00667394 | Completed | Phase 2 | Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | April 2008 | July 2011 |
| NCT00667485 | Completed | Phase 1 | Rapamycin Plus Bevacizumab in Advanced Cancers | April 2008 | May 2012 |
| NCT00670982 | Completed | Phase 2 | Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer | May 2008 | December 2012 |
| NCT00671372 | Completed | Phase 1 | A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer | July 2006 | March 2012 |
| NCT00673673 | Completed | Phase 2 | FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer | May 2008 | July 2014 |
| NCT00675259 | Completed | Phase 2 | Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer | July 2008 | March 2014 |
| NCT00690768 | Completed | Phase 2 | Pars Plana Vitrectomy (PPV) Versus Preoperative Intravitreal Bevacizumab Plus PPV to Treat Diabetic Tractional Retinal Detachment (IBETRA) | March 2008 | May 2008 |
| NCT00691379 | Completed | Phase 1/Phase 2 | Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer | April 2008 | March 2016 |
| NCT00700102 | Completed | Phase 3 | A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. | February 2006 | May 2013 |
| NCT00703976 | Completed | Phase 2 | Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer | October 2008 | September 2014 |
| NCT00705315 | Completed | Phase 1/Phase 2 | Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer | May 2008 | June 2010 |
| NCT00707889 | Completed | Phase 2 | Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer | October 2008 | May 2012 |
| NCT00708448 | Completed | Phase 1 | Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients | March 28, 2008 | August 12, 2010 |
| NCT00710268 | Completed | Phase 1 | Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours | June 2008 | November 2009 |
| NCT00719264 | Completed | Phase 2 | Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer | November 12, 2008 | April 15, 2013 |
| NCT00719797 | Completed | Phase 3 | Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | July 2008 | |
| NCT00720356 | Completed | Phase 2 | Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | July 7, 2009 | July 5, 2018 |
| NCT00723255 | Completed | Phase 2 | Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 2008 | January 25, 2016 |
| NCT00727753 | Completed | VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD) | July 2008 | October 2013 | |
| NCT00729846 | Completed | Phase 2 | Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT) | May 2006 | July 2009 |
| NCT00733408 | Completed | Phase 2 | Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer | April 23, 2008 | September 28, 2017 |
| NCT00734890 | Completed | Phase 1 | Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma | March 2008 | February 2011 |
| NCT00737243 | Completed | Phase 2 | Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site | August 2008 | December 2012 |
| NCT00741195 | Completed | Phase 2 | Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer | April 2008 | October 2016 |
| NCT00741221 | Completed | Phase 2 | Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer | June 2008 | October 2016 |
| NCT00741988 | Completed | Phase 2 | Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer | September 2008 | September 2012 |
| NCT00744718 | Completed | Phase 2 | Bevacizumab and Carboplatin for Patients With Ovarian Cancer | August 2008 | December 2015 |
| NCT00745498 | Completed | N/A | Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy | June 2008 | October 2010 |
| NCT00748657 | Completed | Phase 2 | Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary | September 22, 2008 | January 31, 2013 |
| NCT00753909 | Completed | Phase 2 | Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer | November 2008 | October 2016 |
| NCT00754351 | Completed | Phase 2 | Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer | September 2008 | February 2012 |
| NCT00754650 | Completed | Phase 2 | A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia | September 2008 | March 2009 |
| NCT00755170 | Completed | Phase 2 | Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer | November 2008 | October 2016 |
| NCT00756340 | Completed | Phase 1 | A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors | July 2008 | September 2015 |
| NCT00761644 | Completed | Phase 1 | Doxil, Bevacizumab and Temsirolimus Trial | August 21, 2008 | March 28, 2019 |
| NCT00762034 | Completed | Phase 3 | A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer | December 2008 | December 2014 |
| NCT00762255 | Completed | Phase 1 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | September 2008 | July 2013 |
| NCT00773695 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer | November 7, 2008 | November 9, 2022 |
| NCT00776594 | Completed | Phase 2 | Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy | October 2008 | September 2016 |
| NCT00780494 | Completed | Phase 2 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | February 2009 | December 31, 2017 |
| NCT00781846 | Completed | Phase 1 | Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) | October 2008 | February 2010 |
| NCT00782275 | Completed | Phase 2 | Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | April 2009 | May 2015 |
| NCT00785291 | Completed | Phase 3 | Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer | October 13, 2008 | June 15, 2017 |
| NCT00786643 | Completed | Phase 2 | Study of Gamma Interfereon in Metastatic Colorectal Carcinoma | February 2006 | March 2010 |
| NCT00786669 | Completed | Phase 1 | A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors | October 2008 | November 2012 |
| NCT00795665 | Completed | Phase 2 | Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma | June 2008 | December 2015 |
| NCT00797303 | Completed | Phase 4 | The Effect of Bevacizumab on Corneal Neovascularization | January 2006 | November 2008 |
| NCT00798603 | Completed | Phase 2 | Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | December 2008 | May 2013 |
| NCT00800917 | Completed | Phase 2 | A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme | November 2008 | February 2010 |
| NCT00802906 | Completed | N/A | Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) | May 2007 | December 2010 |
| NCT00803062 | Completed | Phase 3 | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | April 2009 | February 2013 |
| NCT00804921 | Completed | Phase 2 | Effectiveness of Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis in Intraocular Pressure (IOP) After Bevacizumab | ||
| NCT00805649 | Completed | Phase 4 | Combined Therapy in Age-Related Macular Degeneration (ARMD) | January 2006 | July 2008 |
| NCT00805961 | Completed | Phase 2 | RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM | January 2009 | May 2013 |
| NCT00807573 | Completed | Phase 2 | Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment | December 2008 | April 2014 |
| NCT00809133 | Completed | Phase 1 | Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours | May 2007 | February 2015 |
| NCT00816595 | Completed | Phase 2 | Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | February 2009 | November 29, 2016 |
| NCT00819780 | Completed | Phase 2 | PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors | April 24, 2009 | July 7, 2016 |
| NCT00820547 | Completed | Phase 2 | Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients | January 2009 | September 2019 |
| NCT00826540 | Completed | Phase 2 | Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | September 2009 | February 2014 |
| NCT00828009 | Completed | Phase 2 | BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | January 17, 2011 | May 22, 2019 |
| NCT00828672 | Completed | Phase 2 | Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer | June 2009 | March 2019 |
| NCT00843440 | Completed | Phase 2 | Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study | March 2009 | March 2012 |
| NCT00846027 | Completed | Phase 2 | A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer | January 2009 | January 2013 |
| NCT00847119 | Completed | Phase 2 | Xeloda and Bevacizumab to Treat Rectal Cancer | September 2007 | February 2015 |
| NCT00851045 | Completed | Phase 2 | Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer | October 2009 | October 2011 |
| NCT00851136 | Completed | Phase 1 | A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) | May 2009 | June 2010 |
| NCT00853021 | Completed | Phase 2 | Bevacizumab and Aldesleukin in Treating Patients With Metastatic Clear Cell Carcinoma of the Kidney | December 2005 | October 2009 |
| NCT00853073 | Completed | Phase 2/Phase 3 | Does Adding Bevacizumab Therapy in Glaucoma Surgery Improve the Success of Needle Bleb Revisions? | February 2009 | January 2012 |
| NCT00856180 | Completed | Phase 2 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | February 2009 | January 2014 |
| NCT00856492 | Completed | Phase 2 | S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | April 2010 | December 2015 |
| NCT00859222 | Completed | Phase 1/Phase 2 | LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma | March 2009 | December 2015 |
| NCT00861419 | Completed | Phase 1 | To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. | December 2005 | |
| NCT00865189 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Participants With Newly Diagnosed Locally Advanced Rectal Cancer | October 23, 2007 | March 23, 2016 |
| NCT00867321 | Completed | Phase 1/Phase 2 | Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer | April 2009 | May 2013 |
| NCT00868192 | Completed | Phase 2 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | May 2008 | December 2012 |
| NCT00868634 | Completed | Phase 3 | Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer | February 2009 | October 2015 |
| NCT00873756 | Completed | Phase 1 | A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer | May 2009 | April 2014 |
| NCT00874107 | Completed | Phase 2 | Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | June 2009 | May 2016 |
| NCT00874744 | Completed | Phase 2 | Comparison of Single Intravitreal Injection of Triamcinolone or Bevacizumab for the Treatment of Diabetic Macular Edema | March 2008 | October 2008 |
| NCT00875147 | Completed | Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases | April 2009 | September 2009 | |
| NCT00876993 | Completed | Phase 1 | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors | September 2008 | September 2015 |
| NCT00879437 | Completed | Phase 2 | Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | September 1, 2009 | October 2, 2017 |
| NCT00881751 | Completed | Phase 2 | Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer | March 2009 | February 2017 |
| NCT00883688 | Completed | Phase 2 | Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | July 2009 | April 2015 |
| NCT00884741 | Completed | Phase 3 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | April 15, 2009 | March 17, 2013 |
| NCT00885326 | Completed | Phase 1 | N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma | December 2009 | December 2019 |
| NCT00886691 | Completed | Phase 2 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | December 27, 2010 | March 23, 2015 |
| NCT00887536 | Completed | Phase 3 | A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer | May 2009 | February 2018 |
| NCT00887809 | Completed | Phase 2 | Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes | April 2009 | November 2014 |
| NCT00887822 | Completed | Phase 3 | A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer | March 2009 | August 2014 |
| NCT00890786 | Completed | Early Phase 1 | A Study of Bevacizumab Therapy in Patients With Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas | May 2009 | December 2017 |
| NCT00892177 | Completed | Phase 2 | Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme | October 2009 | July 1, 2019 |
| NCT00892710 | Completed | Phase 2 | Trial of Poor Performance Status Patients (ToPPS) | June 2009 | May 2015 |
| NCT00898417 | Completed | Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab | March 14, 2008 | April 14, 2008 | |
| NCT00900172 | Completed | Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel | March 15, 2008 | April 15, 2009 | |
| NCT00904839 | Completed | Phase 2 | BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer | May 2009 | January 2012 |
| NCT00906685 | Completed | Phase 3 | Bevacizumab for Central Retinal Vein Occlusion Study | May 2009 | September 2011 |
| NCT00909987 | Completed | Phase 2 | Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum | March 2009 | June 2013 |
| NCT00911170 | Completed | Phase 3 | PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study | November 3, 2009 | January 2, 2015 |
| NCT00911716 | Completed | N/A | TC Avastin. ICORG 08-10, V6 | October 2008 | September 2015 |
| NCT00911820 | Completed | Phase 2 | Cisplatin, Irinotecan and Bevacizumab (PCA) Versus Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | July 2009 | August 2013 |
| NCT00915603 | Completed | Phase 2 | Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer | July 2009 | July 2014 |
| NCT00920868 | Completed | Phase 1 | XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib | May 2009 | August 2014 |
| NCT00923130 | Completed | Phase 2 | Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer | January 7, 2009 | June 2016 |
| NCT00923936 | Completed | Phase 2 | Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | April 23, 2009 | November 8, 2017 |
| NCT00005061 | Completed | Phase 1 | Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors | December 1999 | |
| NCT00006786 | Completed | Phase 2 | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer | November 2000 | September 2006 |
| NCT00015951 | Completed | Phase 2 | Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | April 2001 | March 2004 |
| NCT00016094 | Completed | Phase 2 | S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma | April 2001 | September 2008 |
| NCT00016107 | Completed | Phase 2 | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer | June 2001 | |
| NCT00016549 | Completed | Phase 2 | Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer | May 13, 2001 | January 29, 2007 |
| NCT00017394 | Completed | Phase 2 | Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer | March 2001 | |
| NCT00019539 | Completed | Phase 2 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | November 1998 | November 2004 |
| NCT00021060 | Completed | Phase 2/Phase 3 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | August 2002 | |
| NCT00022048 | Completed | Phase 1/Phase 2 | Bevacizumab in Treating Patients With Myelodysplastic Syndrome | August 2001 | November 2004 |
| NCT00022607 | Completed | Phase 2 | Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma | January 2002 | May 2006 |
| NCT00022659 | Completed | Phase 2 | Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | April 2002 | March 2010 |
| NCT00023959 | Completed | Phase 1 | Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | July 2001 | |
| NCT00025233 | Completed | Phase 2 | Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix | April 2002 | July 2009 |
| NCT00025337 | Completed | Phase 3 | Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated | September 2001 | |
| NCT00025389 | Completed | Phase 2 | Bevacizumab, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer | November 2001 | August 2007 |
| NCT00026221 | Completed | Phase 2 | Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma | November 2001 | November 2013 |
| NCT00027599 | Completed | Phase 2 | APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | December 2001 | |
| NCT00027703 | Completed | Phase 2 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma | October 2001 | |
| NCT00027885 | Completed | Phase 2 | Phase II Bevacizumab + Tax In Advanced Breast Cancer | November 2001 | August 2010 |
| NCT00028834 | Completed | Phase 2 | Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer | February 2002 | |
| NCT00028990 | Completed | Phase 3 | Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | January 29, 2002 | May 2009 |
| NCT00047710 | Completed | Phase 1 | Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer | September 2002 | July 2006 |
| NCT00049322 | Completed | Phase 2 | Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery | June 2003 | February 2012 |
| NCT00052390 | Completed | Phase 2 | Doxorubicin and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Soft Tissue Sarcoma | October 2002 | October 2005 |
| NCT00052559 | Completed | Phase 1 | Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer | August 2002 | |
| NCT00054132 | Completed | Phase 2 | Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer | December 2002 | April 2015 |
| NCT00055237 | Completed | Phase 2 | Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients | February 26, 2003 | March 15, 2010 |
| NCT00055692 | Completed | Phase 2 | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer | February 2003 | December 2009 |
| NCT00055809 | Completed | Phase 2 | Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors | January 2003 | |
| NCT00055861 | Completed | Phase 2 | Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer | July 2002 | |
| NCT00055913 | Completed | Phase 1/Phase 2 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | March 2003 | |
| NCT00060411 | Completed | Phase 1 | A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer | June 2003 | |
| NCT00062426 | Completed | Phase 3 | Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer | May 2003 | February 2011 |
| NCT00066846 | Completed | Phase 2 | Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy | August 2003 | July 2007 |
| NCT00072046 | Completed | Phase 3 | Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer) | October 2003 | November 2012 |
| NCT00072566 | Completed | Phase 2 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | December 2003 | November 2008 |
| NCT00074308 | Completed | Phase 1/Phase 2 | Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | October 2003 | July 2009 |
| NCT00077298 | Completed | Phase 2 | Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer | December 2003 | July 2007 |
| NCT00079040 | Completed | Phase 2 | Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer | January 2006 | January 2009 |
| NCT00079430 | Completed | Phase 1 | Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | June 2004 | |
| NCT00083031 | Completed | Phase 2 | Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer | July 2003 | August 2009 |
| NCT00084604 | Completed | Phase 2 | Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | April 2004 | |
| NCT00085111 | Completed | Phase 1 | Bevacizumab in Treating Young Patients With Refractory Solid Tumors | December 2003 | |
| NCT00085358 | Completed | Phase 1 | Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) | May 2004 | |
| NCT00088894 | Completed | Phase 3 | Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | June 2004 | |
| NCT00088998 | Completed | Phase 2 | Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer | December 2004 | December 2010 |
| NCT00089609 | Completed | Phase 2 | Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer | April 19, 2005 | January 9, 2018 |
| NCT00091026 | Completed | Phase 2 | Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer | July 2004 | January 2011 |
| NCT00095459 | Completed | Phase 1 | BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | November 2, 2004 | July 20, 2012 |
| NCT00096278 | Completed | Phase 3 | Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer | September 15, 2004 | December 31, 2012 |
| NCT00097019 | Completed | Phase 2 | A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed | February 2005 | May 2006 |
| NCT00098787 | Completed | Phase 2 | Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer | September 8, 2005 | April 2015 |
| NCT00100815 | Completed | Phase 2 | Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer | August 2004 | |
| NCT00100841 | Completed | Phase 2 | Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer | November 2004 | July 2011 |
| NCT00101348 | Completed | Phase 1/Phase 2 | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer | January 2005 | May 2008 |
| NCT00110214 | Completed | Phase 3 | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | April 2005 | August 2011 |
| NCT00112528 | Completed | Phase 2 | Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | June 2005 | November 2010 |
| NCT00112840 | Completed | Phase 1/Phase 2 | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer | May 2005 | September 10, 2015 |
| NCT00112918 | Completed | Phase 3 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer | December 2004 | June 2012 |
| NCT00113217 | Completed | Phase 2 | Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell Carcinoma | February 2005 | August 2012 |
| NCT00114179 | Completed | Phase 2 | Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery | January 2005 | May 2007 |
| NCT00115765 | Completed | Phase 3 | PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study | June 1, 2005 | May 1, 2009 |
| NCT00116506 | Completed | Phase 2 | Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer | January 2005 | July 2007 |
| NCT00118235 | Completed | Phase 2 | Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer | December 2004 | July 2011 |
| NCT00118261 | Completed | Phase 1 | Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer | March 2005 | January 2011 |
| NCT00118755 | Completed | Phase 2 | A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer | July 2005 | |
| NCT00119262 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer | October 2005 | September 2009 |
| NCT00121134 | Completed | N/A | Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer | June 2005 | May 2011 |
| NCT00121199 | Completed | Phase 2 | Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma | June 2005 | December 2010 |
| NCT00121836 | Completed | Phase 4 | A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer | June 2005 | December 2008 |
| NCT00126490 | Completed | Phase 2 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | March 2005 | August 2013 |
| NCT00126503 | Completed | Phase 1/Phase 2 | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer | May 2005 | February 2012 |
| NCT00126542 | Completed | Phase 2 | Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | April 2005 | April 2010 |
| NCT00126633 | Completed | Phase 2 | Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer | April 2004 | October 2008 |
| NCT00129727 | Completed | Phase 2 | Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) | June 2005 | February 2009 |
| NCT00130520 | Completed | Phase 2 | Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer | June 2005 | May 2010 |
| NCT00130728 | Completed | Phase 3 | A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer | June 8, 2005 | December 23, 2019 |
| NCT00137774 | Completed | Phase 2 | Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors | November 2004 | December 2012 |
| NCT00137813 | Completed | Phase 2 | Avastin and Taxotere for Esophagogastric Cancer | August 2004 | September 2009 |
| NCT00137826 | Completed | Phase 2 | Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma | February 2004 | July 2009 |
| NCT00139360 | Completed | Phase 2 | Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma | May 2005 | July 2011 |
| NCT00140556 | Completed | Early Phase 1 | Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer | August 2005 | April 2010 |
| NCT00142467 | Completed | Phase 2 | Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma | April 2004 | June 2011 |
| NCT00142480 | Completed | Phase 2 | Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer | December 2004 | April 2011 |
| NCT00159432 | Completed | Phase 2 | Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer | February 2005 | March 2013 |
| NCT00165568 | Completed | Phase 2 | Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer | July 2005 | October 2006 |
| NCT00177307 | Completed | Phase 2 | Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer | January 2005 | February 2012 |
| NCT00193154 | Completed | Phase 2 | OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma | February 2003 | March 2014 |
| NCT00193219 | Completed | Phase 2 | Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer | July 2005 | July 2010 |
| NCT00193258 | Completed | Phase 1/Phase 2 | Bevacizumab, Erlotinib, and Imatinib in the Treatment of Advanced Renal Cell Carcinoma | June 2004 | August 2011 |
| NCT00193375 | Completed | Phase 2 | Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer | August 2003 | May 2008 |
| NCT00193492 | Completed | Phase 2 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | September 2005 | March 2013 |
| NCT00193622 | Completed | Phase 2 | Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site | April 2004 | January 2009 |
| NCT00203411 | Completed | Phase 2 | Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer | March 2006 | March 2011 |
| NCT00203502 | Completed | Phase 2 | Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer | September 2005 | February 2015 |
| NCT00217425 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms | September 14, 2006 | March 2014 |
| NCT00217503 | Completed | Phase 2 | Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma | July 2005 | June 2007 |
| NCT00217581 | Completed | Phase 2 | Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer | October 2004 | January 2013 |
| NCT00217672 | Completed | Phase 2 | Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer | May 2005 | November 2010 |
| NCT00222469 | Completed | Phase 2 | Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer | August 2005 | May 2007 |
| NCT00222729 | Completed | Phase 2 | Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer | November 2005 | October 2013 |
| NCT00227019 | Completed | Phase 2 | Phase 2 Trial of Bevacizumab in Combination With Pemetrexed | March 2006 | December 2016 |
| NCT00234052 | Completed | Phase 2 | Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | July 28, 2005 | November 28, 2011 |
| NCT00234494 | Completed | Phase 2 | Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer | November 2005 | December 2008 |
| NCT00252564 | Completed | Phase 3 | Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer | September 2005 | June 2009 |
| NCT00254592 | Completed | Phase 2 | Neoadjuvant Treatment of Breast Cancer | October 2005 | September 4, 2013 |
| NCT00255762 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | December 2005 | |
| NCT00257608 | Completed | Phase 3 | A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | January 2006 | November 2014 |
| NCT00262847 | Completed | Phase 3 | Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | September 2005 | April 2015 |
| NCT00265824 | Completed | Phase 3 | Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) | May 2005 | |
| NCT00265850 | Completed | Phase 3 | Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | November 2005 | January 2018 |
| NCT00267696 | Completed | Phase 2 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | November 2005 | December 2013 |
| NCT00268359 | Completed | Phase 2 | Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas | May 2005 | October 2009 |
| NCT00268489 | Completed | Phase 2 | Pemetrexed Disodium and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | May 2006 | April 2010 |
| NCT00271609 | Completed | Phase 2 | Bevacizumab for Recurrent Malignant Glioma | December 2005 | February 2014 |
| NCT00276575 | Completed | Phase 1 | Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors | March 2005 | September 2014 |
| NCT00278889 | Completed | Phase 2 | Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) | January 2006 | October 2009 |
| NCT00280150 | Completed | Phase 1/Phase 2 | Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | January 2006 | January 2013 |
| NCT00281697 | Completed | Phase 3 | A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2) | February 2006 | September 2012 |
| NCT00281840 | Completed | Phase 2 | Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer | September 2005 | December 2012 |
| NCT00287222 | Completed | Phase 2 | Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma | February 2006 | September 2010 |
| NCT00288015 | Completed | Phase 2 | Bevacizumab in Treating Patients With Angiosarcoma | October 2005 | November 10, 2016 |
| NCT00290615 | Completed | Phase 2 | Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery | January 2006 | January 2011 |
| NCT00290810 | Completed | Phase 2 | Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | December 2005 | August 2010 |
| NCT00294931 | Completed | Phase 2 | Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | February 2006 | January 2009 |
| NCT00295503 | Completed | Phase 2 | Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma | February 2006 | August 2010 |
| NCT00301964 | Completed | Phase 2 | Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer | March 2006 | July 2011 |
| NCT00305825 | Completed | Phase 2 | Bevacizumab and Letrozole in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed By Surgery | August 2004 | May 24, 2016 |
| NCT00305877 | Completed | Phase 2 | Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery | February 2006 | February 2012 |
| NCT00307736 | Completed | Phase 1/Phase 2 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | May 2006 | July 2011 |
| NCT00308516 | Completed | Phase 2 | 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer | March 2006 | February 2012 |
| NCT00308529 | Completed | Phase 2 | Irinotecan, Carboplatin, Bevacizumab, and Radiation Therapy in the Treatment of Limited Stage Small Cell Lung Cancer | March 2006 | January 2009 |
| NCT00309998 | Completed | Phase 2 | Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | September 2005 | |
| NCT00312728 | Completed | Phase 2 | A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) | March 2006 | June 2009 |
| NCT00317200 | Completed | Phase 2 | A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer | April 2006 | November 2007 |
| NCT00318136 | Completed | Phase 2 | A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE) | September 2005 | July 2009 |
| NCT00320541 | Completed | Phase 2 | A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer | May 2006 | August 2012 |
| NCT00924820 | Completed | Phase 1/Phase 2 | A Pilot Study of Bevacizumab for Neoplastic Meningitis | June 2009 | September 2015 |
| NCT00929058 | Completed | N/A | Bevacizumab and Vasoconstriction | June 2009 | November 2009 |
| NCT00932438 | Completed | Phase 1/Phase 2 | Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab | June 2009 | December 2012 |
| NCT00937560 | Completed | Phase 2 | A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer | June 25, 2009 | July 1, 2013 |
| NCT00941499 | Completed | Phase 1 | Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab | July 2009 | May 2014 |
| NCT00942331 | Completed | Phase 3 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | July 15, 2009 | June 15, 2021 |
| NCT00942578 | Completed | Phase 2 | A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer | July 16, 2009 | July 31, 2017 |
| NCT00943826 | Completed | Phase 3 | A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma | June 29, 2009 | September 9, 2015 |
| NCT00948675 | Completed | Phase 3 | Study of Participants With Advanced Non-Small Cell Lung Cancer | September 1, 2009 | November 6, 2020 |
| NCT00949247 | Completed | Early Phase 1 | Docetaxel,Carboplatin,Trastuzumab and Bevacizumab for Breast Cancer and Bone Marrow Micrometastases | December 2009 | January 2013 |
| NCT00951496 | Completed | Phase 3 | Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | August 11, 2009 | January 11, 2016 |
| NCT00952029 | Completed | Phase 2/Phase 3 | Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer | March 2010 | January 2018 |
| NCT00954642 | Completed | Phase 1 | A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | August 2009 | December 2011 |
| NCT00959647 | Completed | Phase 2 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | September 2009 | January 2014 |
| NCT00960960 | Completed | Phase 1 | A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer | August 2009 | December 2015 |
| NCT00970684 | Completed | Phase 2 | Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | September 2009 | September 2011 |
| NCT00974584 | Completed | Phase 1 | A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | October 2009 | March 2015 |
| NCT00975897 | Completed | Phase 2/Phase 3 | Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer | July 2009 | December 2012 |
| NCT00976573 | Completed | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma | April 2010 | September 2015 |
| NCT00976911 | Completed | Phase 3 | AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer | October 29, 2009 | July 9, 2014 |
| NCT00980239 | Completed | Phase 1 | HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver | September 2009 | August 2015 |
| NCT00989651 | Completed | Phase 1 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | October 28, 2009 | April 10, 2020 |
| NCT00992121 | Completed | Phase 1 | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | November 18, 2009 | November 1, 2013 |
| NCT00993044 | Completed | Phase 1 | A Study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (Vit-b) in Pediatric and Adolescent Patients With Recurrent or Refractory Solid Tumors of Non-hematopoietic Origin | September 2009 | February 2013 |
| NCT01004172 | Completed | Phase 2 | Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases | November 2009 | February 2017 |
| NCT01004250 | Completed | Phase 2 | A Study of Pemetrexed and Bevacizumab for Participants With Advanced Non-Small Cell Cancer | October 2009 | December 2013 |
| NCT01004874 | Completed | Phase 2 | Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma | December 30, 2009 | November 2, 2021 |
| NCT01005329 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | November 6, 2009 | September 22, 2013 |
| NCT01010126 | Completed | Phase 2 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | September 8, 2009 | March 13, 2017 |
| NCT01013285 | Completed | Phase 2 | Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | June 2006 | August 2015 |
| NCT01015222 | Completed | Phase 1 | Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies | November 2009 | May 27, 2021 |
| NCT01017250 | Completed | N/A | Radiosurgery and Avastin for Recurrent Malignant Gliomas | December 2009 | February 2012 |
| NCT01022541 | Completed | Phase 2 | Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer | June 2006 | February 2015 |
| NCT01024504 | Completed | Phase 2 | Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer | March 2006 | March 2010 |
| NCT01025934 | Completed | Phase 4 | Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy | ||
| NCT01027468 | Completed | N/A | Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration | August 2009 | December 2009 |
| NCT01031381 | Completed | Phase 2 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | September 2010 | December 2014 |
| NCT01032109 | Completed | N/A | Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration | October 2006 | May 2008 |
| NCT01041690 | Completed | N/A | Efficacy of PreOperative Bevacizumab for Diabetic Eye Disease | June 2007 | June 2008 |
| NCT01047293 | Completed | Phase 1/Phase 2 | RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma | May 2010 | August 2015 |
| NCT01048554 | Completed | Phase 2 | Temozolomide Plus Bevacizumab in Patients With Metastatic Melanoma Involving the Central Nervous System | November 2009 | September 2011 |
| NCT01051934 | Completed | Phase 1 | A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | December 29, 2009 | September 28, 2011 |
| NCT01057264 | Completed | Phase 1 | HAI Abraxane With Gemcitabine and Bevacizumab | January 2010 | May 2014 |
| NCT01068977 | Completed | Phase 1 | A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors | August 2007 | January 2010 |
| NCT01069328 | Completed | Phase 1 | Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | July 2006 | October 2011 |
| NCT01075464 | Completed | Phase 1 | A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | February 2010 | April 2013 |
| NCT01083368 | Completed | Phase 1/Phase 2 | Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy | January 2009 | October 2014 |
| NCT01091259 | Completed | Phase 2 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | March 2010 | May 2015 |
| NCT01091792 | Completed | Early Phase 1 | Exploratory Study of the Modulation of the Immune System by VEGF Blockade in Patients With Glioblastoma Multiforme (GBM) | March 2010 | April 2, 2015 |
| NCT01094184 | Completed | Phase 4 | A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer | March 2010 | December 2015 |
| NCT01097746 | Completed | Phase 2 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | April 14, 2010 | September 13, 2022 |
| NCT01102595 | Completed | Phase 2 | Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma | December 2009 | December 2014 |
| NCT01107626 | Completed | Phase 3 | Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer | October 25, 2010 | August 17, 2021 |
| NCT01113476 | Completed | Phase 1 | Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies | April 27, 2010 | August 12, 2022 |
| NCT01115517 | Completed | Phase 2 | Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery | October 2010 | July 2015 |
| NCT01121939 | Completed | Phase 2 | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | May 2010 | August 2015 |
| NCT01125046 | Completed | Phase 2 | Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas | June 17, 2010 | December 31, 2018 |
| NCT01125943 | Completed | N/A | Bevacizumab and Endothelium Dependent Vasodilation | June 2010 | November 2011 |
| NCT01127360 | Completed | Phase 4 | LUCAS (Lucentis Compared to Avastin Study) | March 2009 | August 2014 |
| NCT01137604 | Completed | Phase 2 | A Study in Subjects With Recurrent Malignant Glioma | November 9, 2010 | October 28, 2014 |
| NCT01137968 | Completed | Phase 2 | Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) | May 2010 | September 2013 |
| NCT01139723 | Completed | Phase 1 | A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors | June 2010 | August 2014 |
| NCT01142778 | Completed | Phase 2 | A Study of Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer | May 19, 2010 | December 13, 2017 |
| NCT01146795 | Completed | Phase 2 | Neoadjuvant Therapy for Ovarian Cancer | May 17, 2010 | April 13, 2015 |
| NCT01149850 | Completed | Phase 2 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | April 28, 2010 | December 8, 2023 |
| NCT01152203 | Completed | Phase 1 | Bendamustine and Bevacizumab for Advanced Cancers | June 2010 | May 2014 |
| NCT01163396 | Completed | Phase 2 | First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer | July 2007 | April 2010 |
| NCT01164007 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma | June 30, 2006 | May 31, 2012 |
| NCT01164189 | Completed | Phase 2 | Bevacizumab in Recurrent Grade II and III Glioma | February 2011 | September 24, 2017 |
| NCT01166594 | Completed | Phase 4 | Use of Bevacizumab in Trabeculectomy Surgery | June 2010 | December 2013 |
| NCT01169558 | Completed | Phase 3 | A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum. | May 2006 | July 2009 |
| NCT01180959 | Completed | Phase 2 | Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy | April 14, 2011 | May 19, 2021 |
| NCT01183663 | Completed | Phase 1 | Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | August 2010 | May 2016 |
| NCT01186991 | Completed | Phase 2 | Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer | March 2011 | March 2016 |
| NCT01190345 | Completed | Phase 2 | Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer | May 2010 | October 6, 2017 |
| NCT01193595 | Completed | Phase 1 | Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors | September 2010 | October 2014 |
| NCT01197170 | Completed | Phase 1 | Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | September 7, 2010 | January 13, 2021 |
| NCT01200121 | Completed | Phase 2 | Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers | February 2010 | December 2014 |
| NCT01201265 | Completed | Phase 2 | A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer | February 2011 | April 2015 |
| NCT01205022 | Completed | Phase 1 | Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | April 2011 | January 2014 |
| NCT01206049 | Completed | Phase 2 | Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | September 2010 | March 2016 |
| NCT01206530 | Completed | Phase 1/Phase 2 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | September 2010 | September 2017 |
| NCT01207687 | Completed | Phase 2 | Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) | October 2010 | March 2014 |
| NCT01208103 | Completed | Phase 2 | Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma | May 6, 2011 | March 7, 2018 |
| NCT01209442 | Completed | Phase 2 | Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme | September 16, 2010 | February 3, 2017 |
| NCT01212822 | Completed | Phase 2 | Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer | April 27, 2011 | January 3, 2018 |
| NCT01213238 | Completed | Phase 1 | Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab | September 30, 2010 | September 26, 2018 |
| NCT01215123 | Completed | An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer | January 2010 | July 2012 | |
| NCT01217437 | Completed | Phase 2 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | November 22, 2010 | June 30, 2021 |
| NCT01219777 | Completed | Phase 1 | Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian | September 2010 | May 2015 |
| NCT01222715 | Completed | Phase 2 | Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma | October 2010 | June 2015 |
| NCT01229813 | Completed | Phase 3 | Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer. | October 2010 | December 2013 |
| NCT01229943 | Completed | Phase 2 | Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery | October 15, 2010 | January 3, 2018 |
| NCT01236560 | Completed | Phase 2/Phase 3 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | January 26, 2011 | December 31, 2023 |
| NCT01239732 | Completed | Phase 3 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | December 2010 | March 2015 |
| NCT01243359 | Completed | Phase 1 | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies | October 2010 | |
| NCT01248949 | Completed | Phase 1 | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | October 2010 | October 2015 |
| NCT01251926 | Completed | Phase 1 | EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors | November 15, 2010 | April 23, 2014 |
| NCT01254526 | Completed | Phase 1 | Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer | December 2010 | April 2013 |
| NCT01256762 | Completed | Phase 2 | Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer | November 2010 | December 2012 |
| NCT01260506 | Completed | Phase 1/Phase 2 | Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme | December 2010 | December 20, 2018 |
| NCT01263782 | Completed | Phase 2 | BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | May 17, 2011 | August 15, 2017 |
| NCT01263834 | Completed | Phase 2/Phase 3 | Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome | December 2010 | January 2014 |
| NCT01266031 | Completed | Phase 1/Phase 2 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | July 12, 2011 | January 31, 2017 |
| NCT01274624 | Completed | Phase 1 | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | December 2010 | November 2018 |
| NCT01288404 | Completed | N/A | Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium | January 2008 | November 2010 |
| NCT01290263 | Completed | Phase 1/Phase 2 | Amgen 386 for Recurrent Glioblastoma | December 2010 | January 2017 |
| NCT01290939 | Completed | Phase 3 | Bevacizumab and Lomustine for Recurrent GBM | October 2011 | April 2020 |
| NCT01295944 | Completed | Phase 2 | Carboplatin and Bevacizumab for Recurrent Ependymoma | April 27, 2011 | May 14, 2021 |
| NCT01296815 | Completed | Phase 2 | Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity | September 2010 | December 2013 |
| NCT01298076 | Completed | Phase 2 | Intravitreal Bevacizumab (Avastin®) Versus Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema | October 2010 | September 2014 |
| NCT01301716 | Completed | Phase 1 | A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors | September 2011 | August 2014 |
| NCT01303497 | Completed | Phase 2 | Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas | September 10, 2010 | January 29, 2019 |
| NCT01305213 | Completed | Phase 2 | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | March 21, 2011 | November 3, 2016 |
| NCT01306591 | Completed | N/A | Bevacizumab for Neovascular Age-related Macular Degeneration | January 2008 | December 2010 |
| NCT01309451 | Completed | Phase 4 | Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema | March 2011 | April 2013 |
| NCT01314274 | Completed | Phase 2 | Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | March 2011 | June 2013 |
| NCT01327222 | Completed | Phase 3 | Intravitreal Bevacizumab for Low Vision in Neovascular Age-related Macular Degeneration (AMD) | February 2011 | February 2011 |
| NCT01327612 | Completed | Phase 2 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | March 3, 2011 | February 5, 2020 |
| NCT01332604 | Completed | Phase 1 | GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors | July 2011 | June 2015 |
| NCT01332929 | Completed | Phase 1 | Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis | June 2010 | July 2013 |
| NCT01343901 | Completed | An Observational Study on Bevacizumab (Avastin) as First-Line Treatment in Colorectal Cancer Participants With Potentially Resectable Liver Metastases | September 30, 2010 | June 30, 2015 | |
| NCT01344824 | Completed | Phase 2 | Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers | March 2010 | July 20, 2016 |
| NCT01349660 | Completed | Phase 1/Phase 2 | Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme | December 2011 | December 29, 2018 |
| NCT01351415 | Completed | Phase 3 | A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | June 25, 2011 | June 25, 2016 |
| NCT01364012 | Completed | Phase 3 | A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy | May 23, 2011 | August 17, 2017 |
| NCT01366131 | Completed | Phase 2 | Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) | June 2011 | |
| NCT01368848 | Completed | Phase 2 | Combination of Cisplatin, Docetaxel and Bevacizumab in Patients With Non-small Cell Lung Carcinoma (NSCLC) | April 2010 | December 2012 |
| NCT01374425 | Completed | Phase 2 | Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) | August 2011 | July 2015 |
| NCT01383343 | Completed | Phase 1 | Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer | August 2011 | February 2017 |
| NCT01383707 | Completed | Phase 2 | A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer | August 12, 2011 | May 18, 2016 |
| NCT01390948 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Combination With Temozolomide (TMZ) and Radiotherapy in Paediatric and Adolescent Participants With High-Grade Glioma | October 18, 2011 | January 29, 2020 |
| NCT01397695 | Completed | Phase 2 | Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) | June 2009 | January 2014 |
| NCT01399190 | Completed | An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer | July 2011 | February 2014 | |
| NCT01399684 | Completed | Phase 2 | A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer | November 2011 | February 2014 |
| NCT01408030 | Completed | Phase 2 | North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | August 2011 | September 2014 |
| NCT01442649 | Completed | Phase 2 | Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab | December 2010 | December 31, 2017 |
| NCT01442935 | Completed | Phase 2 | Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases | February 2011 | January 2021 |
| NCT01443676 | Completed | Phase 2 | Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma | October 2011 | August 2016 |
| NCT01445509 | Completed | Phase 1 | Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors | December 29, 2008 | September 20, 2018 |
| NCT01454102 | Completed | Phase 1 | Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | December 16, 2011 | July 23, 2021 |
| NCT01459380 | Completed | Phase 1 | Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | October 11, 2011 | February 11, 2017 |
| NCT01462890 | Completed | Phase 3 | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer | November 2011 | December 2021 |
| NCT01468831 | Completed | Phase 1/Phase 2 | Minocycline to Treat Branch Retinal Vein Occlusion | March 28, 2012 | March 18, 2021 |
| NCT01468844 | Completed | Phase 1/Phase 2 | Minocycline to Treat Central Retinal Vein Occlusion | December 21, 2011 | May 13, 2015 |
| NCT01478594 | Completed | Phase 2 | A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy | December 2011 | January 2015 |
| NCT01481545 | Completed | Phase 2 | Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer | December 2006 | December 2016 |
| NCT01490866 | Completed | Phase 2 | A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) | January 2012 | July 2015 |
| NCT01493843 | Completed | Phase 2 | Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | January 20, 2012 | March 30, 2016 |
| NCT01498328 | Completed | Phase 2 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | December 2011 | May 17, 2016 |
| NCT01501760 | Completed | Phase 3 | Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea | May 13, 2012 | October 2019 |
| NCT01504724 | Completed | Phase 4 | Effect of the Adjunctive IVB Before PRP | August 2011 | August 2013 |
| NCT01506167 | Completed | An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN) | July 6, 2012 | March 10, 2017 | |
| NCT01507480 | Completed | Phase 1 | The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia | October 2011 | December 2012 |
| NCT01514123 | Completed | Phase 1 | Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors | December 29, 2011 | November 16, 2017 |
| NCT01525082 | Completed | Phase 2 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | December 2012 | December 31, 2019 |
| NCT01532089 | Completed | Phase 2 | Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | March 16, 2012 | August 18, 2020 |
| NCT01551745 | Completed | Phase 2 | Salvage Ovarian FANG™ Vaccine + Bevacizumab | March 2012 | April 2016 |
| NCT01554059 | Completed | Phase 2 | Neoadjuvant Chemoradiation With Bevacizumab for Chinese Rectal Cancer Patients | March 2012 | August 2014 |
| NCT01562028 | Completed | Phase 2 | BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) | June 2012 | October 31, 2018 |
| NCT01564914 | Completed | Phase 2 | A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma | May 2012 | June 2015 |
| NCT01572350 | Completed | Phase 3 | Safety and Efficacy of Triamcinolone Acetonide Combined With Laser, Bevacizumab Combined With Laser Versus Laser Alone for the Treatment of Diffuse Non-tractional Diabetic Macular Edema | October 2010 | December 2013 |
| NCT01580969 | Completed | Phase 1/Phase 2 | Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma | July 6, 2012 | May 15, 2018 |
| NCT01588184 | Completed | Phase 4 | An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study | July 13, 2012 | September 27, 2019 |
| NCT01588990 | Completed | Phase 4 | A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer | June 26, 2012 | September 30, 2016 |
| NCT01608087 | Completed | Phase 1 | Pharmacokinetics and Safety Study of BI 695502 in Healthy Subjects | May 1, 2012 | November 1, 2012 |
| NCT01609790 | Completed | Phase 2 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | June 4, 2012 | May 20, 2022 |
| NCT01610557 | Completed | Phase 2 | Ranibizumab and Bevacizumab for Diabetic Macular Edema | May 2012 | February 2015 |
| NCT01621880 | Completed | Phase 2 | Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma | June 2012 | December 2015 |
| NCT01625936 | Completed | Phase 1 | CRLX101 Plus Bevacizumab in Advanced RCC | June 2012 | July 16, 2018 |
| NCT01632228 | Completed | Phase 2 | A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma | June 29, 2012 | January 21, 2016 |
| NCT01633970 | Completed | Phase 1 | A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | July 11, 2012 | February 26, 2020 |
| NCT01648348 | Completed | Phase 1/Phase 2 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | November 2012 | April 15, 2017 |
| NCT01649947 | Completed | Phase 2 | Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | December 23, 2011 | June 30, 2015 |
| NCT01650428 | Completed | Phase 2 | Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery | April 2013 | February 14, 2019 |
| NCT01656304 | Completed | Phase 2 | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | May 2007 | June 2012 |
| NCT01661283 | Completed | Phase 2 | SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | September 2012 | December 2017 |
| NCT01661790 | Completed | Phase 3 | Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer | August 2009 | October 2012 |
| NCT01661946 | Completed | Phase 3 | Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye | August 2012 | August 2013 |
| NCT01664182 | Completed | Phase 2 | Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer | August 1, 2012 | December 7, 2020 |
| NCT01677884 | Completed | Phase 2 | Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy | November 2012 | February 2016 |
| NCT01695772 | Completed | Phase 4 | A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer | October 16, 2012 | May 12, 2016 |
| NCT01700400 | Completed | Phase 1 | Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | September 2012 | October 2014 |
| NCT01705002 | Completed | Phase 1 | Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. | October 2012 | June 2018 |
| NCT01705184 | Completed | Phase 2 | Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer. | December 2012 | October 2017 |
| NCT01712347 | Completed | An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer | October 11, 2012 | July 1, 2016 | |
| NCT01718873 | Completed | Phase 3 | Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer | May 2012 | December 2019 |
| NCT01722162 | Completed | Phase 2 | Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | April 2013 | October 2015 |
| NCT01722968 | Completed | Phase 2 | A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel | November 2012 | |
| NCT01727089 | Completed | Phase 2 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | November 1, 2012 | August 8, 2017 |
| NCT01730950 | Completed | Phase 2 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | December 20, 2012 | December 22, 2022 |
| NCT01736449 | Completed | Phase 4 | Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management | April 2011 | April 2012 |
| NCT01738646 | Completed | Phase 2 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | January 2013 | February 2016 |
| NCT01739218 | Completed | Phase 2 | A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable | February 1, 2013 | August 17, 2016 |
| NCT01740258 | Completed | Phase 2 | Bevacizumab Beyond Progression (BBP) | January 2013 | November 14, 2019 |
| NCT01744756 | Completed | Phase 2/Phase 3 | Subconjunctival Bevacizumab and Recurrent Pterygium | February 2012 | September 2012 |
| NCT01745757 | Completed | Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer | June 2012 | December 2022 | |
| NCT01749384 | Completed | Phase 1 | Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | December 6, 2012 | May 24, 2016 |
| NCT01763645 | Completed | Phase 3 | A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer | October 2012 | November 2014 |
| NCT01763671 | Completed | Phase 3 | Paclitaxel-bevacizumab in Advanced Lung Cancer | May 2013 | April 2017 |
| NCT01767545 | Completed | Phase 4 | Dexamethasone-implant for the Treatment of RVO | September 2010 | February 2012 |
| NCT01767792 | Completed | Phase 2 | Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas | May 15, 2013 | February 1, 2020 |
| NCT01770301 | Completed | Phase 2 | Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) | February 2013 | April 2021 |
| NCT01774474 | Completed | Phase 3 | PRevention of Macular EDema After Cataract Surgery | July 10, 2013 | November 4, 2016 |
| NCT01775644 | Completed | An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE) | December 14, 2012 | May 10, 2019 | |
| NCT01777412 | Completed | Phase 1 | Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations | June 2013 | May 2015 |
| NCT01803282 | Completed | Phase 1 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | March 29, 2013 | April 23, 2019 |
| NCT01811498 | Completed | Phase 1/Phase 2 | Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM | February 2013 | October 2021 |
| NCT01832415 | Completed | First Line Ovarian Cancer Treatment - Cohort Study | April 2013 | March 2016 | |
| NCT01834014 | Completed | N/A | Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases | May 2013 | March 2017 |
| NCT01836653 | Completed | Phase 2 | Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases | May 2013 | March 2017 |
| NCT01837251 | Completed | Phase 3 | Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer | May 2013 | January 2021 |
| NCT01854593 | Completed | Phase 4 | Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy | May 2012 | March 2014 |
| NCT01858649 | Completed | Phase 2 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. | May 2013 | May 2019 |
| NCT01860586 | Completed | N/A | Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. | June 2013 | November 2014 |
| NCT01860638 | Completed | Phase 2 | A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma | August 19, 2013 | May 5, 2017 |
| NCT01891747 | Completed | Phase 1 | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | July 2013 | January 31, 2022 |
| NCT01894061 | Completed | Phase 2 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | June 12, 2013 | July 28, 2019 |
| NCT01898130 | Completed | Phase 2 | Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy | November 27, 2013 | September 5, 2018 |
| NCT01916447 | Completed | Phase 1 | A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors. | September 2013 | September 2017 |
| NCT01918852 | Completed | Phase 3 | S-1 Versus Capecitabine in the First Line Treatment of MCC Patients. | December 2013 | March 2018 |
| NCT01959490 | Completed | Phase 2 | Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer | September 24, 2013 | March 29, 2017 |
| NCT01966003 | Completed | Phase 3 | Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | November 11, 2013 | July 23, 2015 |
| NCT01967810 | Completed | Phase 2 | ANG1005 in Patients With Recurrent High-Grade Glioma | October 2013 | September 2017 |
| NCT01969708 | Completed | Phase 3 | Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) | September 2014 | March 2021 |
| NCT01984242 | Completed | Phase 2 | A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma | January 8, 2014 | January 8, 2019 |
| NCT01989780 | Completed | Phase 2 | Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer | January 2014 | June 2019 |
| NCT01995188 | Completed | Phase 1 | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer | December 16, 2013 | November 9, 2016 |
| NCT01996306 | Completed | Phase 3 | A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC | December 2, 2013 | June 30, 2018 |
| NCT01999270 | Completed | Phase 1 | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | April 2013 | May 2016 |
| NCT02007174 | Completed | Bevacizumab Injection for Recurrent Pterygium | March 2012 | August 2013 | |
| NCT02015351 | Completed | N/A | Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study | September 2012 | October 2018 |
| NCT02022917 | Completed | Phase 2 | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | March 2014 | January 2021 |
| NCT02024607 | Completed | Phase 1/Phase 2 | A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer | January 2014 | November 2019 |
| NCT02036424 | Completed | Phase 4 | Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema | January 2014 | August 2015 |
| NCT02039674 | Completed | Phase 1/Phase 2 | A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | February 21, 2014 | October 18, 2021 |
| NCT02048540 | Completed | Phase 1/Phase 2 | Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell | February 2009 | December 2013 |
| NCT02052648 | Completed | Phase 1/Phase 2 | Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | March 2014 | June 20, 2019 |
| NCT02054052 | Completed | Phase 2 | Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer | January 2014 | March 2019 |
| NCT02076152 | Completed | N/A | FMISO PET Study of Glioblastoma | February 2014 | April 2019 |
| NCT02078648 | Completed | Phase 1/Phase 2 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | May 2014 | January 22, 2018 |
| NCT02093000 | Completed | A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma | November 30, 2014 | January 31, 2018 | |
| NCT02096874 | Completed | Phase 4 | Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema | June 2013 | June 2015 |
| NCT02118831 | Completed | Phase 1/Phase 2 | Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF | March 2012 | April 2014 |
| NCT02119026 | Completed | Phase 2 | Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer | February 2011 | August 31, 2017 |
| NCT02120287 | Completed | Phase 2 | Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme | May 2014 | March 31, 2018 |
| NCT02121990 | Completed | Phase 1 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | April 21, 2014 | August 19, 2020 |
| NCT02158520 | Completed | Phase 2 | Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | October 18, 2013 | October 30, 2019 |
| NCT02174172 | Completed | Phase 1 | A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors | August 18, 2014 | November 25, 2019 |
| NCT02187302 | Completed | Phase 2 | CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC) | July 2014 | January 2017 |
| NCT02192970 | Completed | Phase 2 | Bevacizumab Against Recurrent Retinal Detachment | January 21, 2015 | November 11, 2019 |
| NCT02217956 | Completed | Phase 1 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma | June 2011 | June 2015 |
| NCT02244632 | Completed | Phase 1/Phase 2 | Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer | September 2014 | January 30, 2020 |
| NCT02246049 | Completed | Phase 2 | A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC | May 2014 | February 2017 |
| NCT02248571 | Completed | Phase 4 | Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab | August 2014 | September 30, 2017 |
| NCT02291289 | Completed | Phase 2 | A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) | April 17, 2015 | March 24, 2021 |
| NCT02292758 | Completed | Phase 2 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery | December 12, 2014 | September 27, 2019 |
| NCT02305615 | Completed | An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC) | January 13, 2015 | December 29, 2017 | |
| NCT02305758 | Completed | Phase 2 | Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer | December 2, 2014 | September 22, 2017 |
| NCT02310295 | Completed | N/A | Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema | January 2009 | December 2012 |
| NCT02312245 | Completed | Phase 2 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | July 21, 2015 | April 24, 2023 |
| NCT02313272 | Completed | Phase 1 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | July 28, 2015 | August 9, 2021 |
| NCT02314377 | Completed | Phase 1 | Bevacizumab Therapy for Brain Arteriovenous Malformation | June 2016 | December 1, 2019 |
| NCT02336165 | Completed | Phase 2 | Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma | February 26, 2015 | July 6, 2021 |
| NCT02337491 | Completed | Phase 2 | Pembrolizumab +/- Bevacizumab for Recurrent GBM | February 9, 2015 | September 14, 2020 |
| NCT02342379 | Completed | Phase 2 | TH-302 in Combination With Bevacizumab for Glioblastoma | May 2015 | December 4, 2019 |
| NCT02348008 | Completed | Phase 1/Phase 2 | Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: | March 2015 | December 5, 2019 |
| NCT02354131 | Completed | Phase 1/Phase 2 | Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer | February 15, 2015 | December 15, 2021 |
| NCT02363751 | Completed | Phase 2 | Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24) | December 2014 | August 2020 |
| NCT02366143 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | March 31, 2015 | December 7, 2020 |
| NCT02386826 | Completed | Phase 1 | INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | September 22, 2015 | August 23, 2023 |
| NCT02389959 | Completed | Phase 4 | Intranasal Bevacizumab for HHT-Related Epistaxis | August 4, 2014 | January 23, 2020 |
| NCT02390531 | Completed | Phase 1 | Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity | April 28, 2015 | May 11, 2021 |
| NCT02393898 | Completed | BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older | April 23, 2015 | June 14, 2019 | |
| NCT02396511 | Completed | Phase 2 | TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma | January 2015 | December 2017 |
| NCT02399592 | Completed | Phase 2 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer | March 2015 | July 2019 |
| NCT02420821 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) | May 20, 2015 | December 13, 2021 |
| NCT02456857 | Completed | Phase 2 | Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative | January 12, 2016 | May 24, 2023 |
| NCT02467907 | Completed | Phase 2 | Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer | July 28, 2015 | January 15, 2019 |
| NCT02488330 | Completed | Phase 3 | An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study | August 27, 2015 | June 29, 2018 |
| NCT02511405 | Completed | Phase 3 | A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) | August 2015 | September 30, 2018 |
| NCT02563002 | Completed | Phase 3 | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | November 30, 2015 | July 17, 2023 |
| NCT02574078 | Completed | Phase 1/Phase 2 | A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | November 23, 2015 | April 15, 2020 |
| NCT02582970 | Completed | Phase 4 | A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum | May 2005 | April 2008 |
| NCT02596958 | Completed | Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants | September 2007 | October 2013 | |
| NCT02606305 | Completed | Phase 1/Phase 2 | Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer | March 2, 2016 | March 12, 2021 |
| NCT02613208 | Completed | A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer | December 9, 2015 | December 3, 2018 | |
| NCT02620800 | Completed | Phase 1 | Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer | January 18, 2016 | October 29, 2018 |
| NCT02627144 | Completed | Bevacizumab in Metastatic Renal Cancer | January 2008 | September 2014 | |
| NCT02640365 | Completed | Phase 1 | A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer | November 18, 2015 | December 7, 2016 |
| NCT02641873 | Completed | Phase 1 | A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | December 2015 | January 2017 |
| NCT02659384 | Completed | Phase 2 | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer | December 23, 2016 | March 2022 |
| NCT02665416 | Completed | Phase 1 | Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors | January 25, 2016 | October 30, 2019 |
| NCT02698280 | Completed | Phase 2 | Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma | July 2015 | May 2018 |
| NCT02705274 | Completed | Phase 2/Phase 3 | PRP vs Bevacizumab for PDR Treatment | February 2016 | May 2017 |
| NCT02715531 | Completed | Phase 1 | A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors | April 6, 2016 | May 31, 2021 |
| NCT02753127 | Completed | Phase 3 | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer | June 2016 | May 12, 2021 |
| NCT02754882 | Completed | Phase 3 | A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | July 5, 2016 | October 9, 2018 |
| NCT02767219 | Completed | Phase 3 | The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery | May 2016 | May 2019 |
| NCT02768389 | Completed | Early Phase 1 | Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma | September 6, 2016 | November 2018 |
| NCT02802098 | Completed | Early Phase 1 | Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer | May 2016 | July 2019 |
| NCT02803203 | Completed | Phase 1/Phase 2 | Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers | June 29, 2016 | March 1, 2022 |
| NCT02806817 | Completed | Early Phase 1 | ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism | July 2016 | November 2018 |
| NCT02821559 | Completed | Phase 2 | Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer | July 2012 | |
| NCT02829931 | Completed | Phase 1 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | August 22, 2016 | November 22, 2022 |
| NCT02835833 | Completed | Phase 1 | Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors | June 9, 2016 | June 14, 2018 |
| NCT02848443 | Completed | Phase 1 | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer | May 2016 | April 9, 2020 |
| NCT02853318 | Completed | Phase 2 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | September 1, 2016 | June 30, 2021 |
| NCT02857920 | Completed | Phase 1/Phase 2 | Combination of Bevacizumab and Allogeneic NK Immunotherapy for Metastatic Solid Tumors | August 1, 2016 | August 1, 2019 |
| NCT02876224 | Completed | Phase 1 | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | September 30, 2016 | June 25, 2019 |
| NCT02898012 | Completed | Phase 2 | Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status | October 2010 | June 2013 |
| NCT02901236 | Completed | Phase 2/Phase 3 | Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma | January 2014 | January 2016 |
| NCT02921269 | Completed | Phase 2 | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | March 10, 2017 | January 13, 2021 |
| NCT03032484 | Completed | Phase 2 | TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma | May 18, 2017 | April 5, 2021 |
| NCT03038100 | Completed | Phase 3 | A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 8, 2017 | August 12, 2022 |
| NCT03063762 | Completed | Phase 1 | Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC) | March 20, 2017 | June 14, 2021 |
| NCT03082209 | Completed | Phase 1 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | March 20, 2017 | January 21, 2022 |
| NCT03093155 | Completed | Phase 2 | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | April 3, 2017 | December 29, 2022 |
| NCT03117049 | Completed | Phase 3 | Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | June 13, 2017 | December 4, 2023 |
| NCT03149003 | Completed | Phase 3 | A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy | December 8, 2017 | August 30, 2021 |
| NCT03170284 | Completed | Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer | June 17, 2008 | August 1, 2012 | |
| NCT03196986 | Completed | Phase 3 | mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | August 15, 2017 | July 30, 2021 |
| NCT03227263 | Completed | Phase 3 | BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). | September 28, 2017 | May 15, 2020 |
| NCT03246152 | Completed | Phase 4 | Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA | October 23, 2017 | December 24, 2018 |
| NCT03250832 | Completed | Phase 1 | Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors | August 8, 2017 | February 13, 2023 |
| NCT03334513 | Completed | Refractive Error and Biometry in Retinopathy of Prematurity | April 1, 2011 | April 1, 2014 | |
| NCT03367182 | Completed | Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer | September 1, 2017 | January 31, 2018 | |
| NCT03394885 | Completed | Phase 1/Phase 2 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer | June 19, 2018 | July 20, 2020 |
| NCT03395899 | Completed | Phase 2 | Pre-operative Immunotherapy Combination Strategies in Breast Cancer | December 21, 2017 | August 18, 2023 |
| NCT03396926 | Completed | Phase 2 | Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery | April 18, 2018 | January 30, 2024 |
| NCT03414983 | Completed | Phase 2/Phase 3 | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread | February 20, 2018 | December 28, 2022 |
| NCT03425292 | Completed | Phase 1 | A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer | March 1, 2018 | October 27, 2023 |
| NCT03434379 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | March 15, 2018 | November 17, 2022 |
| NCT03476798 | Completed | Phase 2 | Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium | June 29, 2018 | September 29, 2023 |
| NCT03552770 | Completed | Phase 4 | Single or Combined Protocols for NV-AMD | November 23, 2014 | December 29, 2016 |
| NCT03576651 | Completed | Phase 1 | A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers | March 24, 2018 | December 13, 2019 |
| NCT03577743 | Completed | Phase 2 | Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | July 1, 2018 | February 15, 2021 |
| NCT03635489 | Completed | Phase 3 | A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | August 15, 2018 | May 12, 2023 |
| NCT03694262 | Completed | Phase 2 | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) | July 19, 2019 | April 5, 2023 |
| NCT03698461 | Completed | Phase 2 | Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab | May 15, 2019 | October 24, 2023 |
| NCT03721653 | Completed | Phase 2 | FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients | November 30, 2018 | August 31, 2023 |
| NCT03746041 | Completed | Phase 1 | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | February 14, 2019 | June 6, 2022 |
| NCT03779191 | Completed | Phase 2 | Alectinib in Combination With Bevacizumab in ALK Positive NSCLC | April 8, 2020 | October 30, 2022 |
| NCT03829410 | Completed | Phase 1/Phase 2 | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation | May 6, 2019 | January 29, 2024 |
| NCT03834753 | Completed | Phase 3 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | June 25, 2019 | July 8, 2021 |
| NCT03844074 | Completed | Phase 3 | A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | October 1, 2018 | August 13, 2020 |
| NCT03897192 | Completed | Long-term Outcome of Zonal Outer Retinopathy in Punctate Inner Choroidopathy or Multifocal Choroiditis | October 1, 2018 | March 20, 2019 | |
| NCT03904563 | Completed | Phase 2 | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | January 1, 2019 | December 15, 2022 |
| NCT03919448 | Completed | Phase 1 | A Phase I Study Comparing Pharmacokinetics and Safety of Bevacizumab | April 1, 2019 | September 11, 2019 |
| NCT04091217 | Completed | Phase 2 | Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma | November 25, 2019 | September 1, 2023 |
| NCT04135898 | Completed | Phase 1 | A Study Comparing SIBP-04 and Bevacizumab in Healthy Male Subjects | October 23, 2019 | March 16, 2020 |
| NCT04238169 | Completed | Phase 2 | Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC | September 1, 2020 | December 31, 2023 |
| NCT04247984 | Completed | Phase 2 | A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer | May 1, 2018 | January 31, 2022 |
| NCT04299880 | Completed | Phase 1 | Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols | February 24, 2020 | May 30, 2021 |
| NCT04408118 | Completed | Phase 2 | First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC | October 5, 2020 | December 7, 2023 |
| NCT04426825 | Completed | Phase 2 | A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | September 9, 2020 | February 10, 2023 |
| NCT04446416 | Completed | N/A | Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients | July 21, 2020 | August 4, 2023 |
| NCT04456699 | Completed | Phase 3 | Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003) | August 19, 2020 | November 6, 2023 |
| NCT04516278 | Completed | Phase 3 | A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders | October 1, 2020 | February 10, 2021 |
| NCT04551950 | Completed | Phase 1 | Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046) | October 19, 2020 | June 30, 2022 |
| NCT04677504 | Completed | Phase 2 | A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer | February 23, 2021 | August 25, 2023 |
| NCT04732286 | Completed | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy | May 4, 2021 | April 26, 2024 |
| NCT04737187 | Completed | Phase 3 | Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients | November 25, 2020 | September 12, 2023 |
| NCT04753216 | Completed | Phase 2 | Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | March 16, 2021 | October 25, 2021 |
| NCT04868708 | Completed | Phase 2 | A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer | April 1, 2021 | February 28, 2024 |
| NCT05087992 | Completed | Phase 1 | A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers | November 24, 2021 | November 14, 2023 |
| NCT05110209 | Completed | Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry) | July 15, 2020 | November 20, 2020 | |
| NCT05113511 | Completed | Phase 1 | PK and Safety of SCT510 | May 9, 2018 | July 26, 2021 |
| NCT05146687 | Completed | Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health) | July 15, 2020 | December 11, 2020 | |
| NCT05427305 | Completed | Phase 3 | TAB008 Compared to Avastin® in Patients With EGFR Wild-type Non-squamous Non-small Cell Lung Cancer | October 20, 2017 | March 24, 2020 |
| NCT05718466 | Completed | Phase 3 | Stereotactic Radiology Versus Chemotherapy for Recurrent/Progressive Glioblastoma After Second-Line Chemotherapy | November 2010 | December 2016 |
| NCT05751629 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer | November 15, 2018 | April 1, 2022 |
| NCT05869097 | Completed | Trifluridine/Tipiracil Plus Bevacizumab Versus Trifluridine/Tipiracil Monotherapy in Refractory Metastatic Colorectal Cancer | November 1, 2020 | April 30, 2023 | |
| NCT06031376 | Completed | Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC | July 1, 2019 | March 31, 2023 | |
| NCT04446793 | No longer available | Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer | |||
| NCT02354612 | No longer available | Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial | |||
| NCT05640726 | Not yet recruiting | Phase 2 | The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy | May 1, 2023 | May 1, 2026 |
| NCT06233994 | Not yet recruiting | N/A | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | January 2024 | January 2026 |
| NCT05975463 | Not yet recruiting | Phase 2 | Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy | September 15, 2023 | July 31, 2026 |
| NCT06313970 | Not yet recruiting | Phase 2 | First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients | April 15, 2024 | April 15, 2026 |
| NCT06192680 | Not yet recruiting | Phase 2 | Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | April 1, 2024 | September 30, 2026 |
| NCT06434090 | Not yet recruiting | Phase 1/Phase 2 | Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer | June 5, 2024 | July 1, 2026 |
| NCT04944069 | Not yet recruiting | N/A | Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis | July 2021 | March 2025 |
| NCT06311851 | Not yet recruiting | Phase 1/Phase 2 | Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases | April 1, 2024 | December 1, 2024 |
| NCT04682210 | Not yet recruiting | Phase 3 | Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection | December 2020 | December 2024 |
| NCT03554707 | Not yet recruiting | Early Phase 1 | SGT-53 in Children With Recurrent or Progressive CNS Malignancies | June 2022 | December 2024 |
| NCT06339424 | Not yet recruiting | Phase 2 | Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | March 29, 2024 | March 30, 2031 |
| NCT06039202 | Not yet recruiting | Phase 2 | Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer | January 2024 | October 2025 |
| NCT06341296 | Not yet recruiting | Phase 2 | Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer | June 2024 | December 2026 |
| NCT06160206 | Not yet recruiting | Phase 2 | Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | April 30, 2024 | November 30, 2030 |
| NCT05733598 | Not yet recruiting | Phase 2 | RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC | April 1, 2024 | July 1, 2027 |
| NCT05444088 | Not yet recruiting | Phase 1/Phase 2 | Study of SHR-8068 Combined With Adebrelimab and Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma | August 1, 2022 | June 30, 2026 |
| NCT06361979 | Not yet recruiting | Phase 2 | SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases | May 2024 | May 2026 |
| NCT05976568 | Not yet recruiting | Phase 2/Phase 3 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | September 1, 2023 | September 1, 2027 |
| NCT06163820 | Not yet recruiting | Phase 1/Phase 2 | Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | January 30, 2024 | January 30, 2026 |
| NCT05354674 | Not yet recruiting | Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis | September 1, 2023 | July 1, 2028 | |
| NCT06139211 | Not yet recruiting | Phase 1/Phase 2 | A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors | November 30, 2023 | April 30, 2026 |
| NCT05444374 | Not yet recruiting | Phase 2 | A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer | October 1, 2022 | December 31, 2025 |
| NCT05585814 | Not yet recruiting | Phase 2 | Preoperative Pembrolizumab Plus Bevacizumab Combined With Chemotherapy in Patients With pMMR/MSS Locally Advanced Colorectal Cancer | October 2022 | October 2025 |
| NCT05044871 | Not yet recruiting | Phase 2 | Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | January 1, 2023 | December 1, 2027 |
| NCT05665348 | Not yet recruiting | Phase 2/Phase 3 | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy | February 1, 2023 | April 1, 2026 |
| NCT06447662 | Not yet recruiting | Phase 1 | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | July 28, 2024 | July 12, 2028 |
| NCT06061809 | Not yet recruiting | Phase 2 | N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | July 17, 2024 | December 31, 2030 |
| NCT06336707 | Not yet recruiting | Phase 1 | HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors | April 8, 2024 | April 8, 2028 |
| NCT06294548 | Not yet recruiting | Phase 1/Phase 2 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | October 31, 2024 | May 28, 2028 |
| NCT05588297 | Not yet recruiting | Phase 2 | Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases | October 2022 | October 2025 |
| NCT06393751 | Not yet recruiting | Phase 1/Phase 2 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | June 21, 2024 | February 9, 2028 |
| NCT06245356 | Not yet recruiting | Phase 2 | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer | June 20, 2024 | June 21, 2028 |
| NCT05798819 | Not yet recruiting | Phase 3 | A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | May 1, 2023 | December 1, 2026 |
| NCT06341309 | Not yet recruiting | Phase 1/Phase 2 | Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer | April 1, 2024 | August 1, 2026 |
| NCT06264531 | Not yet recruiting | Phase 2/Phase 3 | Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations | June 2024 | June 2027 |
| NCT06063070 | Not yet recruiting | Phase 2 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | October 18, 2023 | October 30, 2027 |
| NCT06411600 | Not yet recruiting | Phase 2 | Combination Therapy for BRAF-V600E Metastatic CRCm | May 1, 2024 | May 1, 2029 |
| NCT05588388 | Not yet recruiting | Phase 2 | Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases | February 1, 2024 | September 28, 2027 |
| NCT06023862 | Not yet recruiting | Phase 2 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) | January 22, 2024 | December 31, 2029 |
| NCT05096715 | Not yet recruiting | Phase 1 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | January 2022 | January 1, 2026 |
| NCT04988607 | Not yet recruiting | Phase 2 | Osimertinib Plus Bevacizumab in Untreated EGFR Exon21 L858R Mutated NSCLC | August 2021 | May 2025 |
| NCT06184698 | Not yet recruiting | Phase 2 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | January 1, 2024 | December 31, 2025 |
| NCT06329570 | Not yet recruiting | Phase 1/Phase 2 | Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) | July 1, 2024 | March 31, 2027 |
| NCT05906524 | Not yet recruiting | Phase 1/Phase 2 | KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors | April 15, 2024 | December 31, 2025 |
| NCT06439485 | Not yet recruiting | Phase 2 | Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion | November 29, 2024 | February 22, 2030 |
| NCT06268015 | Not yet recruiting | Phase 2 | Botensilimab and Balstilimab Optimization in Colorectal Cancer | July 2024 | July 2028 |
| NCT04405674 | Recruiting | Phase 2 | Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC | July 15, 2020 | March 2025 |
| NCT04404881 | Recruiting | Phase 2 | Bevacizumab In Hereditary Hemorrhagic Telangiectasia | November 23, 2020 | February 1, 2027 |
| NCT05118776 | Recruiting | Phase 3 | Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM | January 21, 2022 | December 31, 2024 |
| NCT04356729 | Recruiting | Phase 2 | A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | August 6, 2020 | September 1, 2025 |
| NCT04310176 | Recruiting | Phase 2 | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer | May 24, 2019 | November 2024 |
| NCT04305106 | Recruiting | Phase 3 | Bevacizumab in Patients With Severe Covid-19 | January 12, 2023 | December 31, 2023 |
| NCT06225622 | Recruiting | Phase 1 | Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | March 11, 2024 | May 1, 2026 |
| NCT04262687 | Recruiting | Phase 2 | Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | April 6, 2021 | September 30, 2024 |
| NCT05799820 | Recruiting | Phase 2 | QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC | September 29, 2022 | September 30, 2025 |
| NCT06285019 | Recruiting | Phase 2 | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma | December 1, 2023 | December 31, 2025 |
| NCT04245865 | Recruiting | Phase 2 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | June 26, 2020 | October 2024 |
| NCT05112965 | Recruiting | Phase 3 | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | December 1, 2021 | December 31, 2025 |
| NCT06241235 | Recruiting | Phase 1/Phase 2 | Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma | March 27, 2024 | May 2026 |
| NCT01269853 | Recruiting | Phase 1/Phase 2 | Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA | October 2010 | October 2026 |
| NCT06282445 | Recruiting | Phase 2 | Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | March 1, 2024 | March 31, 2026 |
| NCT03872947 | Recruiting | Phase 1 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | April 26, 2019 | March 2025 |
| NCT04188145 | Recruiting | Phase 3 | A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer | January 27, 2020 | December 2025 |
| NCT05528952 | Recruiting | Phase 2 | Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | September 27, 2022 | September 30, 2027 |
| NCT05284643 | Recruiting | N/A | Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma | September 30, 2022 | September 30, 2029 |
| NCT04181060 | Recruiting | Phase 3 | Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | December 28, 2020 | December 31, 2026 |
| NCT04180072 | Recruiting | N/A | Atezolizumab Plus Bevacizumab With HCC and HBV Infection | March 12, 2020 | December 31, 2025 |
| NCT03899155 | Recruiting | Phase 2 | Pan Tumor Rollover Study | August 9, 2019 | August 25, 2029 |
| NCT06280495 | Recruiting | Phase 2/Phase 3 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | February 1, 2024 | December 31, 2028 |
| NCT04107168 | Recruiting | Microbiome Immunotherapy Toxicity and Response Evaluation | July 8, 2020 | July 8, 2025 | |
| NCT03912415 | Recruiting | Phase 3 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA) | October 1, 2019 | December 1, 2024 |
| NCT06265350 | Recruiting | N/A | Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases | February 2, 2024 | January 30, 2027 |
| NCT04017455 | Recruiting | Phase 2 | Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN) | October 22, 2019 | August 30, 2024 |
| NCT05828459 | Recruiting | Phase 1 | First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors | July 10, 2023 | July 2027 |
| NCT04008030 | Recruiting | Phase 3 | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) | August 5, 2019 | June 10, 2026 |
| NCT03937830 | Recruiting | Phase 2 | Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma | March 10, 2021 | December 31, 2025 |
| NCT03942328 | Recruiting | Phase 1/Phase 2 | Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | September 19, 2019 | February 29, 2028 |
| NCT05546879 | Recruiting | Phase 1 | Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC | March 15, 2023 | November 15, 2025 |
| NCT05834348 | Recruiting | A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | June 26, 2023 | February 3, 2025 | |
| NCT05440708 | Recruiting | Phase 1/Phase 2 | A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | March 23, 2023 | March 2025 |
| NCT05843188 | Recruiting | Phase 2 | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | August 9, 2023 | October 24, 2026 |
| NCT05854498 | Recruiting | Phase 2 | Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer | October 13, 2023 | July 2026 |
| NCT05863195 | Recruiting | Phase 3 | Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | October 19, 2023 | June 30, 2034 |
| NCT05253651 | Recruiting | Phase 3 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | October 24, 2022 | April 30, 2028 |
| NCT01837862 | Recruiting | Phase 1/Phase 2 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | October 22, 2013 | April 2025 |
| NCT02847559 | Recruiting | Phase 2 | Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | August 2016 | August 2024 |
| NCT05097911 | Recruiting | Phase 1 | Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. | August 2, 2021 | April 2027 |
| NCT05886465 | Recruiting | Phase 2 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | May 24, 2023 | December 1, 2024 |
| NCT05904457 | Recruiting | Phase 2 | A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer | January 2, 2023 | January 31, 2026 |
| NCT05904886 | Recruiting | Phase 3 | A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) | September 14, 2023 | September 1, 2026 |
| NCT02884648 | Recruiting | Phase 2 | Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery | November 15, 2016 | February 1, 2025 |
| NCT02885753 | Recruiting | Phase 3 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver | December 2016 | September 2027 |
| NCT05908786 | Recruiting | Phase 1/Phase 2 | A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | December 5, 2023 | September 30, 2028 |
| NCT06377267 | Recruiting | Phase 2 | Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) | February 6, 2024 | September 2025 |
| NCT05239741 | Recruiting | Phase 3 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | April 2, 2022 | November 10, 2026 |
| NCT01792934 | Recruiting | N/A | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases | May 2013 | July 2025 |
| NCT05065021 | Recruiting | Phase 2 | Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor | February 23, 2023 | June 6, 2025 |
| NCT05603039 | Recruiting | Phase 1/Phase 2 | A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | July 1, 2021 | December 30, 2023 |
| NCT05063552 | Recruiting | Phase 2/Phase 3 | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers | March 13, 2023 | December 15, 2027 |
| NCT05462613 | Recruiting | Phase 2/Phase 3 | Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer | May 9, 2023 | November 2030 |
| NCT02997228 | Recruiting | Phase 3 | Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study | January 19, 2018 | November 30, 2024 |
| NCT05062317 | Recruiting | Phase 2 | ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | April 26, 2022 | February 28, 2026 |
| NCT05983367 | Recruiting | Phase 2 | A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer | October 10, 2023 | August 2028 |
| NCT05616390 | Recruiting | Phase 2 | Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma | November 9, 2022 | November 2025 |
| NCT05999812 | Recruiting | Phase 2 | Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer | December 19, 2023 | October 1, 2028 |
| NCT06003998 | Recruiting | Phase 2 | Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab | December 27, 2022 | January 1, 2025 |
| NCT05039801 | Recruiting | Phase 1 | IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors | September 9, 2021 | May 29, 2026 |
| NCT05029882 | Recruiting | Phase 1 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | October 13, 2021 | November 23, 2025 |
| NCT05022927 | Recruiting | Phase 1 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | June 1, 2021 | December 31, 2025 |
| NCT06011772 | Recruiting | Early Phase 1 | EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer | December 4, 2023 | December 4, 2026 |
| NCT05009082 | Recruiting | Phase 3 | Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer | September 13, 2022 | September 2030 |
| NCT05007132 | Recruiting | Phase 2 | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | December 17, 2021 | December 2032 |
| NCT05627635 | Recruiting | Phase 1/Phase 2 | FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer | May 3, 2023 | April 1, 2025 |
| NCT05636111 | Recruiting | Phase 1 | Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer | July 12, 2023 | July 31, 2026 |
| NCT05007106 | Recruiting | Phase 2 | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) | September 16, 2021 | February 22, 2027 |
| NCT05001880 | Recruiting | Phase 2 | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | March 22, 2022 | August 20, 2025 |
| NCT04999761 | Recruiting | Phase 1 | AB122 Platform Study | June 1, 2021 | May 2026 |
| NCT04982237 | Recruiting | Phase 3 | A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer | August 27, 2021 | December 30, 2025 |
| NCT04981509 | Recruiting | Phase 2 | Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer | June 10, 2022 | December 31, 2024 |
| NCT04974944 | Recruiting | Phase 2 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | July 30, 2021 | December 2024 |
| NCT04973293 | Recruiting | N/A | Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer | October 1, 2022 | December 31, 2024 |
| NCT06031233 | Recruiting | Phase 4 | Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie | September 1, 2023 | December 2024 |
| NCT04958811 | Recruiting | Phase 2 | Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | December 21, 2021 | December 2024 |
| NCT05231122 | Recruiting | Phase 2 | Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer | March 12, 2024 | December 30, 2026 |
| NCT03178552 | Recruiting | Phase 2/Phase 3 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | September 22, 2017 | August 3, 2028 |
| NCT05468242 | Recruiting | Phase 2 | Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy | January 1, 2022 | December 30, 2024 |
| NCT05647122 | Recruiting | Phase 1 | First in Human Study of AZD9592 in Solid Tumors | December 22, 2022 | October 29, 2025 |
| NCT06448364 | Recruiting | Phase 1 | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination | May 9, 2024 | January 1, 2029 |
| NCT04938583 | Recruiting | Phase 1/Phase 2 | Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer | March 17, 2021 | December 31, 2025 |
| NCT04929223 | Recruiting | Phase 1 | A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | October 22, 2021 | April 15, 2026 |
| NCT03203525 | Recruiting | Phase 1 | Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | June 23, 2020 | December 31, 2026 |
| NCT04919629 | Recruiting | Phase 2 | APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | February 17, 2023 | December 1, 2025 |
| NCT06040099 | Recruiting | Phase 2 | A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | February 13, 2024 | July 23, 2026 |
| NCT06047379 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | November 1, 2023 | August 31, 2026 |
| NCT04857684 | Recruiting | Early Phase 1 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | June 18, 2021 | December 31, 2025 |
| NCT02446431 | Recruiting | Early Phase 1 | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | July 2014 | July 2029 |
| NCT05217680 | Recruiting | Phase 3 | Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema | May 17, 2021 | August 31, 2025 |
| NCT06060704 | Recruiting | Phase 2 | Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC. | November 2023 | September 2025 |
| NCT04832776 | Recruiting | Phase 2 | FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases | April 17, 2021 | December 31, 2025 |
| NCT05654454 | Recruiting | Phase 3 | A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | May 31, 2023 | March 2027 |
| NCT04803994 | Recruiting | Phase 3 | The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | July 6, 2021 | April 1, 2025 |
| NCT02285959 | Recruiting | Phase 1 | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme | June 2014 | June 2025 |
| NCT05468359 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | November 7, 2022 | June 2037 |
| NCT05192798 | Recruiting | Phase 2 | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | January 14, 2022 | June 1, 2025 |
| NCT04787289 | Recruiting | Phase 2 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | September 10, 2021 | January 31, 2025 |
| NCT05480306 | Recruiting | Phase 2 | Phase 2 Study of DKN-01 in Colorectal Cancer | August 30, 2022 | October 31, 2025 |
| NCT05185505 | Recruiting | Phase 4 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | January 30, 2023 | October 31, 2027 |
| NCT05180006 | Recruiting | Phase 2 | Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy | February 24, 2022 | February 2026 |
| NCT05717400 | Recruiting | Phase 4 | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy | February 7, 2023 | October 31, 2026 |
| NCT06083844 | Recruiting | Phase 2 | Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy | December 12, 2023 | September 30, 2027 |
| NCT06096779 | Recruiting | Phase 2 | A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis | May 31, 2024 | November 16, 2026 |
| NCT06106308 | Recruiting | Phase 2 | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation | February 27, 2024 | January 2027 |
| NCT03424005 | Recruiting | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | April 2, 2018 | May 3, 2026 |
| NCT06107413 | Recruiting | Phase 2 | Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | November 12, 2023 | October 1, 2026 |
| NCT06109272 | Recruiting | Phase 2/Phase 3 | A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | January 11, 2024 | September 6, 2030 |
| NCT04781270 | Recruiting | Phase 3 | mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases | April 15, 2021 | March 30, 2026 |
| NCT03462212 | Recruiting | Phase 1/Phase 2 | Carboplatin-Paclitaxel-Bevacizumab vs Carbo-Pacli-Beva-Rucaparib vs Carbo-Pacli-Ruca, Selected According to HRD Status, in Patients With Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer, Preceded by a Phase I Dose Escalation Study on Ruca-Beva Combination | March 17, 2021 | March 1, 2025 |
| NCT05464030 | Recruiting | Phase 1 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | August 4, 2022 | February 27, 2026 |
| NCT06121401 | Recruiting | Phase 4 | First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients | September 15, 2023 | September 15, 2027 |
| NCT05739981 | Recruiting | Phase 1/Phase 2 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer | February 10, 2023 | January 30, 2028 |
| NCT05751187 | Recruiting | Phase 2 | Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients | June 27, 2023 | March 30, 2027 |
| NCT06445062 | Recruiting | Phase 1/Phase 2 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | May 24, 2024 | July 15, 2027 |
| NCT03574779 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer | November 15, 2018 | March 31, 2026 |
| NCT05760599 | Recruiting | Phase 2 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | February 27, 2023 | July 1, 2024 |
| NCT04721132 | Recruiting | Phase 2 | Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | February 10, 2021 | December 31, 2027 |
| NCT06125080 | Recruiting | Phase 2 | The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study | October 30, 2023 | October 30, 2026 |
| NCT05769010 | Recruiting | Phase 2 | Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases | March 31, 2023 | April 30, 2026 |
| NCT06133062 | Recruiting | Phase 2 | Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | November 16, 2023 | September 30, 2030 |
| NCT01917877 | Recruiting | Phase 2 | Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab | August 1, 2013 | December 30, 2025 |
| NCT04679064 | Recruiting | Phase 3 | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment | December 1, 2020 | January 1, 2025 |
| NCT05482516 | Recruiting | Phase 3 | Evaluating Novel Therapies in ctDNA Positive GI Cancers | March 29, 2023 | December 2028 |
| NCT03597581 | Recruiting | Phase 1 | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | June 5, 2018 | December 31, 2024 |
| NCT05489211 | Recruiting | Phase 2 | Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | September 6, 2022 | August 19, 2026 |
| NCT04659382 | Recruiting | Phase 2 | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | October 7, 2020 | October 31, 2024 |
| NCT05775159 | Recruiting | Phase 2 | Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | April 24, 2023 | November 25, 2026 |
| NCT04634578 | Recruiting | Phase 2 | Bevacizumab Treatment For Type 1 ROP | May 18, 2022 | December 2026 |
| NCT04607421 | Recruiting | Phase 3 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | December 21, 2020 | November 15, 2026 |
| NCT04587128 | Recruiting | Phase 2 | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | October 19, 2020 | October 2025 |
| NCT04566380 | Recruiting | Phase 2 | ONO-4538 Phase II Rollover Study (ONO-4538-98) | September 10, 2020 | December 31, 2026 |
| NCT04564898 | Recruiting | Phase 1/Phase 2 | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. | January 25, 2022 | March 2025 |
| NCT04563338 | Recruiting | Phase 2 | An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | June 4, 2021 | December 5, 2024 |
| NCT05445778 | Recruiting | Phase 3 | Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) | December 27, 2022 | April 2029 |
| NCT05491811 | Recruiting | Phase 2 | Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation | August 1, 2022 | December 2026 |
| NCT06332079 | Recruiting | Phase 2 | Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients | March 13, 2024 | February 2027 |
| NCT05503667 | Recruiting | Phase 2 | Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma | February 1, 2022 | December 31, 2028 |
| NCT04516447 | Recruiting | Phase 1 | A Study of ZN-c3 in Patients With Ovarian Cancer | October 26, 2020 | February 28, 2027 |
| NCT05776875 | Recruiting | Phase 2 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | June 7, 2023 | August 2025 |
| NCT05160896 | Recruiting | Phase 2 | SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer | November 12, 2021 | June 30, 2023 |
| NCT04512430 | Recruiting | Phase 2 | Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | December 2, 2020 | December 30, 2025 |
| NCT04486352 | Recruiting | Phase 1/Phase 2 | A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | October 20, 2021 | October 2026 |
| NCT01356290 | Recruiting | Phase 2 | Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT | April 2014 | April 2026 |
| NCT05325229 | Recruiting | Phase 2 | A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer | August 18, 2022 | December 2024 |
| NCT05158062 | Recruiting | Phase 2 | Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer | April 20, 2022 | November 30, 2024 |
| NCT05523440 | Recruiting | Phase 2 | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | February 15, 2023 | January 2027 |
| NCT05781308 | Recruiting | Phase 2 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | April 26, 2023 | June 2026 |
| NCT06323382 | Recruiting | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | January 1, 2021 | December 30, 2024 | |
| NCT05797246 | Recruiting | Phase 2 | Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP) | August 2, 2023 | November 2, 2026 |
| NCT06190093 | Recruiting | Phase 3 | A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | January 24, 2024 | October 2024 |
| NCT04449874 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | July 29, 2020 | November 30, 2024 |
| NCT03768063 | Recruiting | Phase 3 | A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study | February 28, 2019 | July 5, 2028 |
| NCT05797467 | Recruiting | Phase 3 | Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients | April 1, 2023 | April 1, 2033 |
| NCT05303259 | Recruiting | Phase 2 | Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury | November 1, 2021 | December 30, 2025 |
| NCT06433869 | Recruiting | Phase 2 | The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites | December 14, 2023 | December 31, 2026 |
| NCT05525767 | Recruiting | Phase 4 | Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer | March 31, 2022 | December 31, 2025 |
| NCT06307249 | Recruiting | Phase 1 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA | February 15, 2023 | December 2027 |
| NCT04739670 | Recruiting | Phase 2 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | March 1, 2021 | September 30, 2025 |
| NCT05337137 | Recruiting | Phase 1/Phase 2 | A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer | May 5, 2022 | December 15, 2026 |
| NCT05727163 | Recruiting | Phase 2 | FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients | July 29, 2022 | December 31, 2026 |
| NCT06117891 | Recruiting | An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | November 27, 2023 | February 1, 2027 | |
| NCT05170594 | Recruiting | Phase 2 | A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer | December 24, 2021 | June 30, 2024 |
| NCT01933815 | Suspended | Phase 1/Phase 2 | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma | August 2013 | May 2025 |
| NCT03024437 | Suspended | Phase 1/Phase 2 | Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma | June 29, 2017 | June 30, 2024 |
| NCT02162537 | Terminated | Phase 3 | Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases | December 2013 | January 2019 |
| NCT02179567 | Terminated | Phase 2 | Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC | March 2010 | March 2013 |
| NCT00702819 | Terminated | Phase 1 | Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity | June 2008 | July 2009 |
| NCT05448677 | Terminated | Phase 2 | Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma | December 15, 2022 | March 8, 2024 |
| NCT02250118 | Terminated | Phase 1 | Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer | December 9, 2014 | October 17, 2017 |
| NCT00694200 | Terminated | Phase 2 | Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer | April 2008 | December 2009 |
| NCT00684996 | Terminated | Phase 1/Phase 2 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer | June 2008 | October 2010 |
| NCT02343549 | Terminated | Phase 2 | A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM) | January 2015 | July 11, 2020 |
| NCT00107315 | Terminated | Phase 2 | Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer | July 2004 | |
| NCT02387957 | Terminated | Phase 2 | A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer) | April 26, 2016 | January 2017 |
| NCT00096148 | Terminated | Phase 2 | Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | October 2004 | |
| NCT02414165 | Terminated | Phase 2/Phase 3 | The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma | November 30, 2015 | December 20, 2019 |
| NCT00679029 | Terminated | Phase 2 | Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer | May 2, 2008 | November 18, 2010 |
| NCT05648006 | Terminated | Phase 2 | First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer | October 17, 2023 | April 15, 2024 |
| NCT02490878 | Terminated | Phase 2 | Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases | April 2016 | December 15, 2022 |
| NCT00070122 | Terminated | Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer | April 2004 | |
| NCT00674011 | Terminated | Hypertension in Breast Cancer Patients Receiving Bevacizumab | January 2008 | September 2010 | |
| NCT00049088 | Terminated | Phase 1 | Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors | August 2002 | |
| NCT00651482 | Terminated | Phase 2 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) | August 2008 | March 2012 |
| NCT02648711 | Terminated | Phase 1 | Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors | October 2015 | May 7, 2018 |
| NCT02654639 | Terminated | Phase 2 | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | February 2016 | November 2017 |
| NCT02661815 | Terminated | Phase 1 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | June 15, 2016 | July 28, 2017 |
| NCT02663271 | Terminated | Phase 2 | TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma | December 19, 2016 | June 11, 2021 |
| NCT02664961 | Terminated | Phase 2 | Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) | March 2016 | November 2018 |
| NCT00632541 | Terminated | Phase 2 | A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer | October 2007 | March 2009 |
| NCT00626561 | Terminated | Phase 2 | Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix | February 2008 | July 2011 |
| NCT00625898 | Terminated | Phase 3 | BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab | April 2008 | July 2014 |
| NCT02743078 | Terminated | Phase 2 | Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma | May 9, 2017 | October 15, 2019 |
| NCT00609622 | Terminated | Phase 2 | Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer | April 2008 | July 2011 |
| NCT00043004 | Terminated | Phase 2 | Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer | May 2002 | |
| NCT00602329 | Terminated | Phase 2 | MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer | February 2006 | October 2009 |
| NCT00023920 | Terminated | Phase 2 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia | July 2001 | |
| NCT02833701 | Terminated | Phase 1 | Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma | March 2016 | March 2019 |
| NCT00601926 | Terminated | Phase 2 | Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | February 2008 | May 2013 |
| NCT02841332 | Terminated | N/A | Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma | May 2013 | December 2016 |
| NCT02842580 | Terminated | Phase 2 | De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer | September 2016 | October 2020 |
| NCT00583622 | Terminated | Phase 2 | Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients | December 2007 | January 2012 |
| NCT02923739 | Terminated | Phase 2 | Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | May 5, 2017 | September 27, 2022 |
| NCT00570531 | Terminated | Phase 2 | Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma | June 2007 | June 2013 |
| NCT00565656 | Terminated | Phase 2 | A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts | July 2007 | July 2010 |
| NCT02982694 | Terminated | Phase 2 | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | November 24, 2017 | November 27, 2020 |
| NCT02988843 | Terminated | Phase 2 | Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors | March 29, 2017 | December 15, 2019 |
| NCT03050814 | Terminated | Phase 2 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | April 5, 2017 | August 25, 2021 |
| NCT00544700 | Terminated | Phase 3 | Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer | November 26, 2007 | December 12, 2019 |
| NCT03136406 | Terminated | Phase 1/Phase 2 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | August 11, 2017 | November 1, 2019 |
| NCT00537823 | Terminated | Phase 2 | Pre- and Post-operative FOLFOX Based Therapy for Patients With Colorectal Cancer With Liver Involvement | June 2007 | July 2011 |
| NCT03176264 | Terminated | Phase 1 | PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer | September 25, 2017 | January 30, 2018 |
| NCT00536939 | Terminated | Phase 2 | Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer | November 2007 | March 2008 |
| NCT00531076 | Terminated | Phase 1 | Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer | October 2007 | January 2010 |
| NCT03272217 | Terminated | Phase 2 | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer | September 13, 2017 | March 17, 2022 |
| NCT00523809 | Terminated | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor | August 2007 | October 2011 |
| NCT00520975 | Terminated | Phase 3 | Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU | November 2007 | October 2015 |
| NCT00517361 | Terminated | Phase 2 | Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer | August 2007 | April 2012 |
| NCT00508872 | Terminated | Phase 2 | Folfox-B Study for Patients With Colorectal Liver Metastases | November 2005 | June 2009 |
| NCT00499369 | Terminated | Phase 3 | Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy | June 2007 | November 2012 |
| NCT03367871 | Terminated | Phase 2 | Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer | September 6, 2018 | January 30, 2023 |
| NCT03368859 | Terminated | Phase 2 | A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab | March 20, 2018 | December 18, 2019 |
| NCT03376659 | Terminated | Phase 1/Phase 2 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | August 8, 2018 | August 1, 2023 |
| NCT03382886 | Terminated | Phase 1 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma | April 11, 2018 | July 2, 2019 |
| NCT00491738 | Terminated | Phase 2 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) | August 2007 | |
| NCT03387098 | Terminated | Phase 1/Phase 2 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | December 28, 2017 | January 15, 2019 |
| NCT00486759 | Terminated | Phase 3 | A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | July 26, 2007 | November 30, 2011 |
| NCT00476827 | Terminated | Phase 2 | A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain | May 2007 | May 2011 |
| NCT00924209 | Terminated | Phase 2 | A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer | March 2009 | September 2011 |
| NCT00925652 | Terminated | Phase 2 | Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer | September 2010 | January 30, 2019 |
| NCT00461773 | Terminated | Phase 2 | Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer | March 2007 | May 2010 |
| NCT00934440 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma | June 2009 | November 2015 |
| NCT00449163 | Terminated | Phase 2 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | March 1, 2006 | March 2010 |
| NCT00946712 | Terminated | Phase 3 | S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer | July 15, 2009 | February 8, 2022 |
| NCT03555149 | Terminated | Phase 1/Phase 2 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | September 27, 2018 | September 26, 2022 |
| NCT00440973 | Terminated | Phase 2 | Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer | October 2006 | November 2007 |
| NCT03573986 | Terminated | Phase 1 | Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment | April 18, 2018 | January 14, 2020 |
| NCT00955305 | Terminated | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | March 2010 | November 2016 |
| NCT00960297 | Terminated | Phase 2 | Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC | August 2009 | May 2013 |
| NCT00972335 | Terminated | Phase 2 | Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma | January 2010 | July 2014 |
| NCT00438204 | Terminated | Phase 2 | Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | May 2006 | June 2016 |
| NCT00976677 | Terminated | Phase 2 | Carboplatin, Paclitaxel, and Bevacizumab With or Without Erlotinib Hydrochloride in Treating Non-Smokers With Advanced Non-Small Cell Lung Cancer | January 2010 | November 2013 |
| NCT00913913 | Terminated | Phase 2 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients | February 2009 | January 2013 |
| NCT00434356 | Terminated | Phase 2 | A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) | March 2007 | |
| NCT00996502 | Terminated | Phase 1/Phase 2 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | July 2006 | March 2010 |
| NCT00434226 | Terminated | Phase 2 | A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) | March 2007 | |
| NCT03690739 | Terminated | Phase 3 | Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer | August 9, 2019 | March 3, 2021 |
| NCT01012297 | Terminated | Phase 3 | Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma | November 2009 | September 2015 |
| NCT03713944 | Terminated | Phase 2 | Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | November 15, 2018 | December 16, 2021 |
| NCT00426829 | Terminated | Phase 1 | Proton Therapy and Bevacizumab for Primary Liver Tumors | May 2007 | November 2009 |
| NCT00424840 | Terminated | Phase 1 | Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy | June 2006 | March 2014 |
| NCT00418093 | Terminated | Phase 2 | Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma | September 2006 | October 2011 |
| NCT01046279 | Terminated | Hypertension Monitoring in Glioma Patients Treated With Bevacizumab | January 2010 | August 2012 | |
| NCT01055028 | Terminated | Phase 2 | Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma | February 2010 | June 24, 2016 |
| NCT01057212 | Terminated | Phase 2 | Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | February 2010 | December 2013 |
| NCT00410774 | Terminated | Phase 1/Phase 2 | Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been Completely Removed By Surgery | July 2006 | October 2007 |
| NCT01069796 | Terminated | Phase 2 | Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer | April 2010 | June 2014 |
| NCT01086345 | Terminated | Early Phase 1 | Radiosurgery Plus Bevacizumab in Glioblastoma | February 2010 | December 2014 |
| NCT00408070 | Terminated | Phase 2 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | October 2006 | October 2009 |
| NCT01095809 | Terminated | Phase 3 | Efficacy, Safety and Tolerability of Repeated Dosis of Intravitreous Bevacizumab in Uveitic Macular Oedema | April 2010 | April 2013 |
| NCT01105702 | Terminated | Phase 2 | Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma | May 2010 | April 2015 |
| NCT01120158 | Terminated | Phase 2 | Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer | September 2009 | January 2017 |
| NCT01133990 | Terminated | Phase 1/Phase 2 | FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer | March 4, 2010 | February 18, 2011 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00866723 | Terminated | Phase 2 | Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer | March 2009 | June 2012 |
| NCT01182350 | Terminated | Phase 2 | Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) | September 2011 | June 2016 |
| NCT01189240 | Terminated | Phase 1/Phase 2 | RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | December 2010 | February 2015 |
| NCT00402883 | Terminated | Phase 2 | Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer | November 2006 | January 2009 |
| NCT00850577 | Terminated | Phase 2 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | June 2009 | August 2013 |
| NCT01198158 | Terminated | Phase 3 | Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy | September 15, 2010 | December 16, 2017 |
| NCT01198548 | Terminated | Phase 2 | High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer | August 2010 | June 2012 |
| NCT00393094 | Terminated | Phase 2 | Bevacizumab and Irinotecan to Treat Brain Tumors | September 2006 | March 2010 |
| NCT04068610 | Terminated | Phase 1/Phase 2 | COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC | September 13, 2019 | October 10, 2022 |
| NCT00392665 | Terminated | Phase 2 | Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck | October 2006 | December 2013 |
| NCT00378573 | Terminated | Phase 2 | Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | January 2007 | September 2008 |
| NCT04099836 | Terminated | Phase 2 | Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | July 9, 2020 | June 15, 2023 |
| NCT00369551 | Terminated | Phase 1 | Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer | June 2006 | |
| NCT00369070 | Terminated | Phase 2 | A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | January 31, 2007 | August 3, 2011 |
| NCT00356681 | Terminated | Phase 2 | A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer | December 2006 | August 2012 |
| NCT00351039 | Terminated | Phase 1/Phase 2 | Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With Non-Small Cell Lung Cancer | July 2006 | September 2008 |
| NCT01264341 | Terminated | Phase 2 | Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma | December 2010 | July 2015 |
| NCT00334763 | Terminated | Phase 2 | Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer | May 2006 | November 2007 |
| NCT01279681 | Terminated | Phase 3 | Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer | January 2011 | November 1, 2014 |
| NCT01280643 | Terminated | N/A | Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | March 2010 | May 2014 |
| NCT01303679 | Terminated | Phase 3 | 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer | June 2010 | May 2018 |
| NCT00327093 | Terminated | Phase 4 | Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases | May 2006 | October 2008 |
| NCT01312376 | Terminated | Phase 1 | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | March 2011 | January 2019 |
| NCT01320683 | Terminated | Phase 2 | Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer | March 2011 | December 2014 |
| NCT04421378 | Terminated | Phase 1/Phase 2 | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma | June 8, 2020 | July 3, 2023 |
| NCT01339039 | Terminated | Phase 1 | Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | December 2011 | April 8, 2017 |
| NCT00326911 | Terminated | Phase 2 | Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer | May 2006 | December 2008 |
| NCT01375816 | Terminated | Phase 2 | Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer | May 2011 | December 2014 |
| NCT04541173 | Terminated | Phase 2 | Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | November 30, 2020 | June 30, 2023 |
| NCT01408953 | Terminated | Phase 2 | Therapeutic Study of Bevacizumab Injection Directly Inside the Keloid Tissue | February 2012 | November 2012 |
| NCT04634604 | Terminated | Phase 3 | A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP | April 27, 2022 | August 14, 2023 |
| NCT01471054 | Terminated | Phase 2 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | April 2014 | July 2015 |
| NCT01478321 | Terminated | Phase 2 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | December 14, 2011 | September 12, 2018 |
| NCT00324987 | Terminated | Phase 3 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor | April 2008 | July 2015 |
| NCT01495988 | Terminated | Phase 2 | Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | August 2013 | June 2016 |
| NCT04681677 | Terminated | Phase 2 | Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab | November 2, 2021 | April 24, 2024 |
| NCT00321100 | Terminated | Phase 2 | Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab | April 12, 2006 | December 18, 2013 |
| NCT01508000 | Terminated | Phase 2 | Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases | June 2013 | September 2016 |
| NCT00314353 | Terminated | Phase 2 | Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon | March 2006 | June 2010 |
| NCT01578551 | Terminated | Phase 2 | Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. | May 2012 | January 2017 |
| NCT00307723 | Terminated | Phase 1/Phase 2 | Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer | May 2006 | July 2009 |
| NCT01582152 | Terminated | Phase 1/Phase 2 | Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | July 2012 | March 2016 |
| NCT00303628 | Terminated | Phase 3 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer | May 11, 2006 | February 11, 2019 |
| NCT00296062 | Terminated | Phase 1 | Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer | March 2006 | May 2011 |
| NCT04861948 | Terminated | Phase 1 | IBI188 Combination Therapy in Solid Tumors | May 25, 2021 | July 30, 2022 |
| NCT00293332 | Terminated | Phase 2 | Docetaxel, Carboplatin, and Bevacizumab in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery | December 2005 | April 2007 |
| NCT00281528 | Terminated | Phase 2 | Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer | February 1, 2006 | March 1, 2011 |
| NCT00804830 | Terminated | Phase 2 | Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer | April 2008 | December 2014 |
| NCT01690325 | Terminated | Phase 2 | Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) | September 2012 | November 2016 |
| NCT00280007 | Terminated | Phase 2 | Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | January 2006 | December 2010 |
| NCT04954014 | Terminated | Phase 2 | Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients | September 1, 2020 | August 31, 2021 |
| NCT01705392 | Terminated | Phase 2 | Bevacizumab vs Dacarbazine in Metastatic Melanoma | January 2013 | February 20, 2017 |
| NCT00804206 | Terminated | Phase 4 | Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation | July 2008 | July 2008 |
| NCT01759238 | Terminated | Phase 2 | Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer | May 2013 | October 2014 |
| NCT01765582 | Terminated | Phase 2 | Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer | January 23, 2013 | March 14, 2016 |
| NCT00779311 | Terminated | Phase 1 | A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer | October 2008 | March 2011 |
| NCT05093608 | Terminated | Phase 1 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | November 3, 2021 | October 12, 2022 |
| NCT01814813 | Terminated | Phase 2 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | May 2013 | May 1, 2023 |
| NCT01821859 | Terminated | Phase 2 | Abraxane/Bevacizumab | January 2010 | November 2011 |
| NCT00268450 | Terminated | Phase 2 | Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery | September 21, 2005 | April 2012 |
| NCT01847677 | Terminated | Phase 2 | Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin | May 6, 2013 | May 17, 2019 |
| NCT00766246 | Terminated | Phase 2 | Phase II Avastin Trial for Stage IIIB/IV NSCLC | October 2008 | April 2012 |
| NCT00755118 | Terminated | Phase 2 | Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc | October 2008 | August 2012 |
| NCT01936974 | Terminated | Phase 2 | (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma | September 2013 | August 2015 |
| NCT01937715 | Terminated | Phase 1/Phase 2 | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | February 2014 | August 2015 |
| NCT00749567 | Terminated | Phase 2 | Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer | July 2008 | September 2010 |
| NCT00728845 | Terminated | Phase 1/Phase 2 | Hydroxychloroquine, Carboplatin, Paclitaxel, and Bevacizumab in Recurrent Advanced Non-Small Cell Lung Cancer | June 16, 2008 | December 21, 2010 |
| NCT00227617 | Terminated | Phase 2/Phase 3 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | June 8, 2005 | February 2016 |
| NCT00720512 | Terminated | Phase 3 | Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab | June 2008 | March 2014 |
| NCT00717990 | Terminated | Phase 2 | Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment | April 2008 | December 2012 |
| NCT02047214 | Terminated | Phase 2 | Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy | January 2014 | December 2015 |
| NCT00127036 | Terminated | Phase 2 | Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | October 2003 | December 2010 |
| NCT02079519 | Terminated | Phase 2 | A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma | May 2006 | May 2008 |
| NCT02106520 | Terminated | Phase 2/Phase 3 | Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) | April 2014 | September 2015 |
| NCT02141295 | Terminated | Phase 2 | A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer | June 30, 2014 | February 1, 2017 |
| NCT00370370 | Unknown status | Phase 3 | Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD | November 2005 | |
| NCT01044329 | Unknown status | Phase 2 | Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Branch Retinal Vein Occlusion | January 2010 | December 2010 |
| NCT01770171 | Unknown status | Phase 2 | Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer | April 2012 | December 2017 |
| NCT00559715 | Unknown status | Phase 3 | Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab | August 2008 | August 2010 |
| NCT02942043 | Unknown status | Phase 2 | Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer | October 2016 | October 2019 |
| NCT05068206 | Unknown status | Phase 2 | A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx | October 8, 2021 | June 2024 |
| NCT02930954 | Unknown status | Phase 2 | Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | November 2016 | December 2018 |
| NCT01802645 | Unknown status | Phase 2 | Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases | March 2013 | December 2020 |
| NCT02296567 | Unknown status | Phase 2/Phase 3 | Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients | December 2014 | July 2016 |
| NCT02919371 | Unknown status | Phase 1/Phase 2 | Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) | December 2014 | December 2021 |
| NCT02054078 | Unknown status | Phase 2 | Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion | January 2012 | |
| NCT01818973 | Unknown status | Phase 2 | Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer | March 2013 | March 2020 |
| NCT02072720 | Unknown status | Early Phase 1 | Angiogenic Factor Expression During Fractionated Irradiation | February 2014 | May 1, 2021 |
| NCT00404404 | Unknown status | Phase 2 | ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer | October 2006 | |
| NCT03990103 | Unknown status | Phase 2 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | November 1, 2017 | April 30, 2022 |
| NCT00854529 | Unknown status | Phase 2 | Subconjunctival Bevacizumab Effect on Bleb Vascularity | April 2009 | October 2011 |
| NCT02842294 | Unknown status | Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer | May 2013 | February 2018 | |
| NCT04003792 | Unknown status | Phase 2 | Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. | January 1, 2020 | January 2022 |
| NCT01167725 | Unknown status | Phase 3 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer | August 2010 | |
| NCT02250599 | Unknown status | Phase 2 | Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma | August 2014 | December 2016 |
| NCT01838538 | Unknown status | Phase 2 | Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy | June 2011 | |
| NCT05357417 | Unknown status | Phase 2 | Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases | April 29, 2022 | May 2024 |
| NCT04072198 | Unknown status | Phase 2 | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients | September 26, 2019 | September 2022 |
| NCT01852409 | Unknown status | Phase 1 | Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites | May 2013 | June 2015 |
| NCT03925233 | Unknown status | Breast Cancer Treatment Based on Organ-like Culture | January 2, 2019 | December 15, 2021 | |
| NCT02759614 | Unknown status | Phase 3 | Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations | April 1, 2016 | June 1, 2019 |
| NCT04097444 | Unknown status | Phase 2 | CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC | October 11, 2019 | August 31, 2022 |
| NCT00370721 | Unknown status | Phase 3 | Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR) | March 2006 | |
| NCT01217398 | Unknown status | Phase 2 | Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye | October 2009 | |
| NCT00370669 | Unknown status | Phase 3 | Effect of Intravitreal Bevacizumab on Clinically Significant Macular Edema | November 2005 | February 2007 |
| NCT01220154 | Unknown status | Phase 1 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | October 2010 | |
| NCT03912402 | Unknown status | Phase 2 | Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA) | December 25, 2018 | July 7, 2020 |
| NCT01229202 | Unknown status | Phase 4 | Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery | July 2008 | June 2012 |
| NCT04138992 | Unknown status | Phase 2/Phase 3 | A Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer | August 1, 2020 | May 31, 2022 |
| NCT04148898 | Unknown status | Phase 2 | Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis | November 1, 2019 | July 1, 2021 |
| NCT01860144 | Unknown status | An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer | June 2012 | December 2015 | |
| NCT00262067 | Unknown status | Phase 3 | A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) | December 2005 | December 2013 |
| NCT04175158 | Unknown status | Phase 1 | Clinical Trial in Chinese Healthy Volunteers of GB222 | April 24, 2017 | November 2020 |
| NCT02743923 | Unknown status | Phase 3 | Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer | April 2016 | April 2024 |
| NCT01249638 | Unknown status | Phase 3 | Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC | December 2010 | December 2016 |
| NCT03896074 | Unknown status | Phase 2 | Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) | May 2019 | April 2023 |
| NCT00873236 | Unknown status | Phase 2 | MRI Scans of Blood Vessel Changes Caused by Bevacizumab Alone or Given Together With Interferon Alpha-2a in Treating Patients With Stage III or Stage IV Kidney Cancer | April 2008 | |
| NCT00703235 | Unknown status | Phase 2/Phase 3 | Intravitreal Bevacizumab for Diabetic Macular Edema | ||
| NCT04213222 | Unknown status | Radiomics Assess of Bevacizumab Plus Chemo in Colorectal Cancer Liver Metastases | October 2020 | December 2023 | |
| NCT00348998 | Unknown status | Phase 2 | Bevacizumab, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer | April 2006 | |
| NCT03872661 | Unknown status | Phase 2 | Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC | March 1, 2019 | March 1, 2024 |
| NCT01274273 | Unknown status | Phase 2 | Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer | October 2009 | December 2015 |
| NCT01880385 | Unknown status | Phase 1 | Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer | March 2011 | April 2017 |
| NCT00622726 | Unknown status | Phase 2 | Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity | March 2008 | August 2020 |
| NCT03832179 | Unknown status | Phase 4 | Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification | November 15, 2018 | October 30, 2022 |
| NCT01093235 | Unknown status | Phase 3 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer | April 2009 | |
| NCT04303988 | Unknown status | Phase 2 | A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases. | March 30, 2020 | January 30, 2022 |
| NCT01091896 | Unknown status | Phase 2 | Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage | January 2010 | March 2011 |
| NCT03813394 | Unknown status | Phase 1/Phase 2 | Bevacizumab and Pembrolizumab Combination in EBER-ISH Positive NPC | May 1, 2019 | March 1, 2024 |
| NCT02672995 | Unknown status | Phase 1 | Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial | January 2018 | December 2018 |
| NCT00408408 | Unknown status | Phase 3 | Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery | November 2006 | March 2018 |
| NCT00898794 | Unknown status | Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer | October 2007 | ||
| NCT01912443 | Unknown status | Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer | August 2013 | ||
| NCT00640640 | Unknown status | N/A | The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD) | August 2007 | February 2009 |
| NCT03792074 | Unknown status | Phase 3 | To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer | February 2019 | January 2022 |
| NCT02645734 | Unknown status | Phase 2/Phase 3 | The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema | ||
| NCT02594423 | Unknown status | Phase 4 | Strategies for Management of Corneal Neovascularisation | December 2015 | August 2018 |
| NCT04425681 | Unknown status | Phase 2 | Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer | October 1, 2017 | June 1, 2021 |
| NCT03711240 | Unknown status | Phase 2 | The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases | January 8, 2019 | October 30, 2020 |
| NCT02555800 | Unknown status | Phase 2 | Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis | December 2014 | June 2017 |
| NCT05363722 | Unknown status | Phase 1 | A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma | May 2022 | April 2024 |
| NCT00433927 | Unknown status | Phase 3 | 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer (CRC) | January 2007 | December 2016 |
| NCT03647956 | Unknown status | Phase 2 | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | October 1, 2018 | April 3, 2020 |
| NCT04525326 | Unknown status | Phase 3 | Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver Metastases | October 1, 2020 | November 1, 2022 |
| NCT04527068 | Unknown status | Phase 2 | QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | September 20, 2020 | February 1, 2022 |
| NCT02226289 | Unknown status | Phase 2 | Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment | September 2020 | December 2020 |
| NCT00999791 | Unknown status | Phase 1 | Intravitreal Diclofenac Versus Avastin as Primary Treatment of Diffuse Diabetic Macular Edema | July 2009 | |
| NCT04556071 | Unknown status | Phase 2 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | November 6, 2020 | October 1, 2022 |
| NCT05396937 | Unknown status | Phase 2 | Efficacy and Safety of T+A+RAD in HCC | January 12, 2022 | December 2023 |
| NCT00992849 | Unknown status | Phase 2 | Bevacizumab for the Treatment of Corneal Neovascularization | May 2009 | April 2012 |
| NCT03631836 | Unknown status | Phase 1 | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma | January 1, 2019 | January 1, 2022 |
| NCT03616691 | Unknown status | Phase 2 | Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC | August 1, 2018 | June 30, 2020 |
| NCT04575415 | Unknown status | Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | October 7, 2020 | December 2023 | |
| NCT04627363 | Unknown status | Phase 2 | HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | January 1, 2021 | June 30, 2023 |
| NCT03611179 | Unknown status | Phase 2 | Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer | September 1, 2018 | September 1, 2022 |
| NCT02530801 | Unknown status | Phase 4 | Strategies for Management of Recurrent Pterygium | January 2017 | August 2018 |
| NCT02521051 | Unknown status | Phase 1/Phase 2 | Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer | October 2015 | June 2022 |
| NCT03607643 | Unknown status | Phase 1/Phase 2 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | January 15, 2019 | December 15, 2020 |
| NCT01966913 | Unknown status | Phase 1/Phase 2 | Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors | April 2012 | September 2020 |
| NCT01487629 | Unknown status | Phase 2 | Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema | April 2010 | September 2012 |
| NCT00436709 | Unknown status | N/A | Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer | July 2006 | |
| NCT00974389 | Unknown status | Phase 2 | S-1 and Bevacizumab in Treating Patients With Colorectal Cancer That is Recurrent or Cannot Be Removed by Surgery | July 2009 | |
| NCT02515734 | Unknown status | Phase 2 | A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab | August 2015 | June 2020 |
| NCT00438737 | Unknown status | Phase 2 | Cetuximab, Leucovorin, Oxaliplatin, and Fluorouracil With or Without Bevacizumab in Treating Patients With Resectable Liver Metastases From Colorectal Cancer | January 2007 | |
| NCT00162669 | Unknown status | Phase 2 | Bevacizumab in Advanced Hepatocellular Carcinoma | May 2005 | |
| NCT04689347 | Unknown status | Phase 1 | 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer. | January 1, 2021 | January 2023 |
| NCT00957125 | Unknown status | Phase 2 | A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | September 2008 | November 2016 |
| NCT00150657 | Unknown status | Phase 2 | Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer | November 2004 | |
| NCT04725448 | Unknown status | Phase 2 | Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | April 6, 2021 | November 30, 2023 |
| NCT00318513 | Unknown status | Phase 1 | Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema | ||
| NCT03533127 | Unknown status | Phase 3 | A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer | November 27, 2017 | December 28, 2020 |
| NCT00815594 | Unknown status | Phase 4 | Bleb Vascularity Change After Subconjunctival Injection Bevacizumab | December 2008 | May 2009 |
| NCT00450203 | Unknown status | Phase 2/Phase 3 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | October 2007 | December 2017 |
| NCT04741165 | Unknown status | Phase 2 | Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) | January 7, 2021 | October 30, 2022 |
| NCT02462304 | Unknown status | Phase 4 | To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema | June 2015 | December 2017 |
| NCT02005120 | Unknown status | Phase 2 | Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC | December 2013 | December 2015 |
| NCT04776655 | Unknown status | Phase 3 | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB | April 30, 2021 | April 29, 2024 |
| NCT04788381 | Unknown status | The Effects of Preoperative Bevacizumab on Perioperative Complications | April 1, 2021 | July 31, 2021 | |
| NCT00684853 | Unknown status | Phase 2 | Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD | November 2007 | |
| NCT00513266 | Unknown status | Phase 2 | Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery | June 2007 | |
| NCT00301990 | Unknown status | Phase 2 | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer | September 2005 | |
| NCT01635790 | Unknown status | Phase 2/Phase 3 | Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME) | June 2012 | |
| NCT01635803 | Unknown status | Phase 2/Phase 3 | Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO) | June 2012 | |
| NCT03303495 | Unknown status | Phase 3 | A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | November 14, 2011 | December 31, 2018 |
| NCT01652560 | Unknown status | Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy | June 2012 | September 2014 | |
| NCT03240549 | Unknown status | Phase 2 | Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease | August 2017 | September 30, 2019 |
| NCT00710229 | Unknown status | Phase 3 | Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration | July 2008 | |
| NCT05273814 | Unknown status | Phase 1 | Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer | August 1, 2022 | February 1, 2024 |
| NCT00524875 | Unknown status | N/A | Effect of Intravitreal Bevacizumab on Early Post-Vitrectomy Hemorrhage in Diabetic Patients | January 2007 | September 2007 |
| NCT01679327 | Unknown status | Phase 2 | Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer | March 2012 | September 2014 |
| NCT02023710 | Unknown status | Phase 2 | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | December 2013 | December 2017 |
| NCT02339116 | Unknown status | Phase 3 | Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC | February 26, 2015 | February 2021 |
| NCT02330783 | Unknown status | Phase 2 | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | December 2014 | December 2018 |
| NCT05314101 | Unknown status | Phase 2 | TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | April 1, 2022 | February 28, 2024 |
| NCT02139579 | Unknown status | Phase 2 | Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer | May 2014 | |
| NCT04973904 | Unknown status | Phase 2 | Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer | August 1, 2021 | December 1, 2023 |
| NCT04988191 | Unknown status | Phase 1/Phase 2 | Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer | December 24, 2020 | December 24, 2023 |
| NCT00538005 | Unknown status | Phase 1/Phase 2 | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | May 2007 | |
| NCT00544011 | Unknown status | Phase 2 | Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer | April 2007 | |
| NCT03126071 | Unknown status | Phase 2 | Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer | February 15, 2017 | February 15, 2023 |
| NCT05009017 | Unknown status | Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients | January 1, 2021 | December 31, 2022 | |
| NCT00797485 | Unknown status | Phase 3 | Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery | July 2008 | |
| NCT03115762 | Unknown status | Phase 1 | Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects | June 2017 | July 2017 |
| NCT03095001 | Unknown status | Phase 2 | Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion | June 1, 2017 | June 1, 2020 |
| NCT02195336 | Unknown status | N/A | dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact. | August 2014 | June 2018 |
| NCT00557713 | Unknown status | Phase 2 | XELOX+Bevacizumab Followed by Capecitabine+Bevacizumab+Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | February 2007 | October 2013 |
| NCT04466917 | Withdrawn | Phase 3 | A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | May 15, 2021 | November 13, 2022 |
| NCT00118105 | Withdrawn | Phase 2 | S0408: Capecitabine, Oxaliplatin, and Bevacizumab in Pts Undergoing Surgery for Liver Mets From Colorectal Cancer | November 2006 | April 2007 |
| NCT03708536 | Withdrawn | Phase 3 | Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma | November 2018 | November 2022 |
| NCT00908219 | Withdrawn | Phase 2 | A Study of Bevacizumab to Prevent Malignant Ascites | July 2009 | February 2011 |
| NCT04510584 | Withdrawn | Phase 2 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | July 16, 2021 | February 22, 2023 |
| NCT03693573 | Withdrawn | Phase 3 | A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma | January 11, 2019 | January 31, 2024 |
| NCT05431582 | Withdrawn | Phase 1 | Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | December 14, 2022 | December 14, 2022 |
| NCT00524069 | Withdrawn | N/A | Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery | January 2007 | |
| NCT05070104 | Withdrawn | Phase 1 | CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer | March 30, 2023 | November 1, 2024 |
| NCT01782976 | Withdrawn | Phase 2 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | June 2013 | |
| NCT03197584 | Withdrawn | Phase 1/Phase 2 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy | December 2017 | April 2019 |
| NCT00253526 | Withdrawn | Phase 2 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | ||
| NCT03197571 | Withdrawn | Phase 1/Phase 2 | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03806049 | Withdrawn | Phase 3 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | December 2019 | December 2024 |
| NCT01674738 | Withdrawn | Phase 2 | TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV | ||
| NCT02754362 | Withdrawn | Phase 2 | A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma | November 2016 | June 2019 |
| NCT00406380 | Withdrawn | Phase 3 | Effect of Avastin in Juxtafoveal Telangiectasias | September 2006 | November 2006 |
| NCT01159236 | Withdrawn | N/A | Molecular Triaging of Newly Diagnosed Breast Cancer | September 2010 | |
| NCT02065466 | Withdrawn | Phase 1/Phase 2 | Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases | July 2014 | August 2015 |
| NCT00988897 | Withdrawn | Phase 2 | Colorectal Cancer RECHALLENGE | October 2009 | May 2012 |
| NCT00984438 | Withdrawn | Phase 1/Phase 2 | Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme | June 2009 | June 2010 |
| NCT03843853 | Withdrawn | Phase 2 | Pemetrexed and S-1 in Combination With Bevacizumab in Refractory Colorectal Cancer | May 1, 2019 | May 1, 2022 |
| NCT02036723 | Withdrawn | Phase 3 | Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration | ||
| NCT05410301 | Withdrawn | N/A | Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma | April 2023 | August 2026 |
| NCT03175666 | Withdrawn | Phase 1/Phase 2 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | December 2017 | March 2019 |
| NCT03169790 | Withdrawn | Phase 1/Phase 2 | QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL | December 2017 | March 2019 |
| NCT03836157 | Withdrawn | Phase 2 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | May 31, 2019 | May 2022 |
| NCT00845104 | Withdrawn | Phase 2 | Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment | January 2009 | |
| NCT00411593 | Withdrawn | Phase 1/Phase 2 | Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC) | November 2006 | May 2007 |
| NCT03169777 | Withdrawn | Phase 1/Phase 2 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | August 2018 | March 2019 |
| NCT03169764 | Withdrawn | Phase 1/Phase 2 | QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT02229175 | Withdrawn | Phase 2/Phase 3 | Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema | January 1, 2021 | January 1, 2027 |
| NCT03169738 | Withdrawn | Phase 1/Phase 2 | QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | February 2018 | March 2019 |
| NCT01262859 | Withdrawn | Phase 2 | Pilot Study for Locally Advanced Head and Neck Cancer | December 2010 | July 2011 |
| NCT03167177 | Withdrawn | Phase 1/Phase 2 | QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy | December 2017 | March 2019 |
| NCT03167164 | Withdrawn | Phase 1/Phase 2 | QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy | December 2017 | March 2019 |
| NCT00571740 | Withdrawn | Phase 2 | Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer | ||
| NCT05886257 | Withdrawn | Phase 2 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | December 7, 2022 | March 31, 2023 |
| NCT01314066 | Withdrawn | Phase 2 | Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS) | July 2010 | February 2016 |
| NCT00801866 | Withdrawn | Phase 4 | Avastin for Post-photocoagulation Macular Edema | December 2008 | December 2008 |
| NCT03563144 | Withdrawn | Phase 2 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | August 2018 | December 30, 2019 |
| NCT01540435 | Withdrawn | Phase 2 | Perioperative Treatment of Resectable Liver Metastases | September 2012 | May 2013 |
| NCT00408772 | Withdrawn | Phase 2 | Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer | June 2007 | April 2008 |
| NCT00556205 | Withdrawn | Phase 2 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | September 2009 | September 2009 |
| NCT00755157 | Withdrawn | Phase 2 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | April 2008 | August 2012 |
| NCT01063010 | Withdrawn | N/A | Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock | February 2010 | January 2015 |
| NCT05510427 | Withdrawn | Phase 1 | Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification | August 7, 2023 | August 7, 2023 |
| NCT00469469 | Withdrawn | Phase 2 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | May 2007 | September 2009 |
| NCT02413853 | Withdrawn | Phase 2 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer | November 2015 | November 2018 |
| NCT05238831 | Withdrawn | Early Phase 1 | SMMART Adaptive Clinical Treatment (ACT) Trial | January 30, 2023 | May 31, 2026 |
| NCT00600210 | Withdrawn | Phase 2 | Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer | January 2008 | April 2011 |
| NCT06006286 | Withdrawn | Phase 1/Phase 2 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | August 8, 2023 | November 10, 2023 |
| NCT00469976 | Withdrawn | Phase 2 | Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer | June 2007 | |
| NCT03380689 | Withdrawn | Phase 1 | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer | January 5, 2018 | January 5, 2019 |
| NCT00406172 | Withdrawn | Phase 3 | Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) | November 2006 | November 2006 |
| NCT00496405 | Withdrawn | Phase 4 | Unilateral Bevacizumab for Bilateral Diabetic Macular Edema | April 2007 | October 2007 |
| NCT01232777 | Withdrawn | Phase 2 | Pan-VEGF Blockade for the Treatment of Retinopathy of Prematurity (BLOCK-ROP) | June 2012 | July 2018 |
| NCT03037736 | Withdrawn | Phase 4 | Outpatient Performed Pterygium Surgery Study | March 1, 2020 | March 1, 2020 |
| NCT00407121 | Withdrawn | Phase 3 | Intravitreal Bevacizumab for Inflammatory Neovascular Membranes | December 2006 | December 2006 |
| NCT02348255 | Withdrawn | Phase 2 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | January 2016 | January 2017 |
| NCT01270438 | Withdrawn | Phase 2 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | December 2010 | August 2013 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Avastin
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2004
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2007
- Target (Drug list of Screening Committee of Anticancer Drugs)
- VEGF
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 大腸がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 非小細胞肺がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 乳がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- グリオブラストーマ
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 腎細胞がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 卵巣がん
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 悪性神経膠腫
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 子宮頸がん?